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Over the last century, significant changes in nutrition, lifestyle habits, and therapeutic successes 
against many infectious diseases have led to the emergence, on the world stage, of a series of non-
communicable diseases. These conditions are responsible for most of the causes of mortality and 
morbidity not only in Western countries but also in the developing world. 
The marked increase in the incidence of obesity, which has reached the levels of a real pandemic, 
has led to a parallel growth of all the pathologies that make up the so-called Metabolic Syndrome. 
Metabolic-dysfunction associated with fatty liver disease (MAFLD), formally known as non-
alcoholic fatty liver disease (NAFLD), can be considered the liver manifestation of Reven 
Syndrome.  
Currently, also thanks to the introduction of new drugs for the treatment of the hepatitis C infection, 
it appears to be the most common cause of chronic medical liver disease in the Western world and 
its prevalence is rapidly increasing also in Asian countries, following the changes in eating habits 
and a more sedentary lifestyle 1 2. 
According to current guidelines and consensus recommendations, NAFLD is characterized by the 
accumulation of hepatocytes fatty vacuoles, in subjects with no history of significant alcohol 
consumption or with no other identifiable secondary causes responsible for steatosis. 
In the nineteenth century, Addison and subsequently Rokitansky highlighted the existence of a 
correlation between alcohol intake and the accumulation of fat in the hepatocyte.  
In 1884, Pepper described the presence of fatty liver in a subject with a diabetes diagnosis, and in 
the following year, Bartholow suggested the potential association between this condition and 
obesity 3. 
However, it was in the second half of the 1900s that the association between hepatic steatosis and 
altered glucose metabolism and insulin resistance (IR) was demonstrated, as it was first detected in 
animals and eventually also in human beings 4. 
In 1962, Thaler postulated the existence of a pathogenetic relationship between fatty liver and the 
development of cirrhosis 5. 
In 1980, Ludwig described 20 subjects whose liver biopsy presented histopathological 
characteristics typical of the picture that he defined as non-alcoholic steatohepatitis 6.  
Currently, the NAFLD denomination has become an “umbrella term”: it includes a wide spectrum 
of histological disorders ranging from simple liver steatosis (non-alcoholic fatty liver NAFL) to 
steatohepatitis (NASH), up to cirrhosis and hepatocellular carcinoma, observed in subjects with a 
daily alcohol consumption below 30 g and 20 g/day respectively in men and women, and in whom 
secondary causes of liver steatosis were excluded. 
The gold standard for the diagnosis of steatosis and non-alcoholic steatohepatitis, according to the 
international societies’ guidelines, is represented by liver biopsy, a procedure that is not devoid of 
risks and is sometimes rejected by the patients themselves.  
For this reason, several authors have tried, over the years, to identify non-invasive tools (from 
imaging and radiological investigations to humoral markers) that can help the physician to 
recognize patients suffering from this pathology, staging NAFLD and predicting evolutive risk to 
define their better follow-up. For this purpose, different types of serum biomarkers have been 
proposed, such as cytokeratin 18 (CK-18), fibroblastic growth factor 21 (FGF-21) or a combined 
panel of soluble markers. 
It has recently been observed that the levels of the immunocomplex resulting from the interaction 
between IgM and squamous cell carcinoma antigen (SCAA) correlate with the severity of the 
chronic medical liver disease, as they are higher in patients with fibrosing disease and 
hepatocellular carcinoma (HCC) compared to those with non-advanced pathology. However, it is 
not clear whether this is also applicable in patients with metabolic liver disease. 
Moreover, in the last years robust evidence supports the role of genetic predisposition in NAFLD 
and HCC development; variants in the genes involved in the regulation of hepatic lipid 
metabolisms, such as PNPLA3, TM6SF2, MBOAT7, and GCKR, are strongly associated with 
hepatic fat content (HFC) and progression of liver diseases.  
The principal aim of this study is, therefore, to determine whether patients with histologically well-
characterized cohorts of non-alcoholic fatty liver disease, in their different patterns of degrees of 
manifestation, have an autonomous production of SCCA-IgM/Serpin B3.  
Secondly, we examine the impact of a polygenic risk score of hepatic fat content (PRS-HFC), based 
on well-characterized risk variants, on NAFLD-HCC in a cross-sectional cohort of at-risk 
individuals (NAFLD cross-sectional cohort), and we attempt to optimize it by adjusting for a 





NAFLD refers to a broad spectrum of pathologies affecting liver parenchyma, which are observed 
in subjects without evidence of significant consumption of alcoholic beverages, ranging from 
simple hepatic steatosis to steatohepatitis and cirrhosis. The finding of more than 5% of steatosis 
affecting hepatocytes, in the absence of secondary causes that could justify it, can be detected 
through a radiological (spectroscopic or selective magnetic resonance for the study of the water/fat 
ratio) or histological investigation 7, 8. 
The pathological evaluation of a biopsy sample in subjects with hepatic steatosis (NAFL) highlights 
the presence of fat vacuoles within more than 5% of hepatocytes. In the case of steatohepatitis 
(NASH), the presence of multifocal inflammation of the hepatic parenchyma, Mallory's hyaline 
bodies, phenomena of hepatocyte damage such as apoptosis and ballonization, in association or not 
with sinusoidal fibrosis is noted 7,9. For the certain diagnosis of steatohepatitis, it is, therefore, 
necessary to perform a histological study 7. It is estimated that about 10-30 % of NAFL patients 
develop liver cirrhosis and several papers suggest that over 70% of cases of cirrhosis classified as 
cryptogenic could be attributed to an unrecognized NAFLD. 
In most patients, the presence of NAFLD is associated with the presence of metabolic risk factors, 
such as obesity, type II diabetes mellitus, or dyslipidaemia 8.  
Furthermore, the concomitance of secondary causes of steatosis, the most frequent of which are 
listed in table 1, should be excluded. 
In the scientific community, there is no univocal consensus regarding the limits to be adopted 
concerning the level of hepatotoxicity secondary to alcohol consumption 10. The European 
guidelines indicate the limit for the daily consumption of alcoholic beverages at 30 and 20 grams 
respectively for men and women 7. The American ones consider 210/140 grams of alcohol per week 
as cut-offs for men and women respectively and recommend that candidates for clinical trials 
should be abstinent for more than 2 years 8. Finally, Asian standards apply even more restrictive 
limits referring to 140/70 grams of alcohol per week 11. 
Nevertheless, some authors point out that these limits would be particularly arbitrary as the alcohol-
induced liver damage does not depend only on the amount of alcohol consumed but also on the 
type, individual susceptibility or genetic predisposition, gender, sex, duration, and methods of 
exposure. In particular, subjects with metabolic risk factors, despite moderate alcohol consumption, 
still risk developing NAFLD, as it would seem that the weight of the former, on the risk of 
developing hepatic steatosis, is much greater than consumption of alcoholic beverages alone 12. 
Finally, it should be remarked that some papers seem to describe a protective role played by the 
intake of moderate amounts of alcohol concerning the development of hepatic steatosis itself 13. 
Epidemiological studies propose the existence of a J-shaped curve between mortality and alcohol 
intake 14 identifying as the turning point an average alcohol intake of about 25-30 g and 40 g 
respectively in women and men 15,16.  In 2017 Alberg et al. published the results of an 
epidemiological study conducted in Finland between 2000 and 2001 on a cohort of 6732 
participants. Among the results of their study, it emerges that in the subgroup in which the subjects 
reported alcohol consumption within the limits recommended by the definition of NAFLD, alcohol 
intake, albeit in limited quantities, represents a significant risk factor for development of liver 
disease. This suggests that there may not be any safety limits regarding the use of alcoholic 
beverages concerning the risk of liver damage. It could be speculated that alcohol consumption and 
obesity synergistically increase the risk of liver disease progression 17.  
During the first months of 2020, a consensus of international experts proposed the adoption of the 
acronym MAFLD (metabolic dysfunction associated fatty liver disease), as a more comprehensive 
term, instead of NAFLD 18,19, converting a “negative” definition in one based on positive criteria. 
The newly proposed nomenclature is applied to patients with fatty liver (detected by histology, 
imaging, or blood biomarker) and contemporary presence of at least one of the following 
conditions: type 2 diabetes, overweight or obesity, lean or normal weight with evidence of 
metabolic abnormalities (presence of two or more of the following states: increased waist 
circumference, hypertension, hypertriglyceridemia, low levels of high-density lipoprotein (HDL) 
cholesterol, prediabetes, high levels of High sensitivity C-reactive protein (hs-PCR), high 
Homeostasis Model Assessment (HOMA)-insulin resistance score). This new definition better 
reflects the set of current knowledge relating to the mechanisms of metabolic disfunction that 
support the development of fatty liver disease. Alcohol consumption no longer represents a 
diagnostic criterion, according to the experts, MAFLD may occur with other liver diseases, 
including alcoholic ones, in this way authors attempt to avoid the stigmatization of patients. All 
these considerations enlarge the investigative scope and allow us to reach new therapy options. 
However, heterogeneity of this definition may make a better patient stratification and 
characterization in different subtypes necessary.  Lin et al. 20 tested and evaluated in the real world, 
a population derived from the 1988-1994 NAHANES USA database, the new definition of MAFLD 
compared with the NAFLD one. They observed that the new definition was more practical to 
identify patient with fatty liver disease - in particular those at higher risk of disease progression. 
Patients with MAFLD results were older, with higher BMI, with higher metabolic comorbidities, 
present higher HOMA-IR index and higher levels of lipid and liver enzymes. Patients with alcohol 
consumption were younger, more frequently male, with higher levels of transaminase, and with 
more severe fibrosis. However, the two terms are not interchangeable: not all subjects with MAFLD 
have NAFLD and vice versa (nearly 15% discrepancy could be observed) 21. Other authors, such as 
Younossi et al.22 warn of a premature change in the nomenclature, which could prove 
counterproductive, and could inadequately describe NAFLD heterogeneity. The new definition does 
not address the main limitations in this field, particularly regarding pathophysiology, risk 
stratification, and molecular phenotyping, and management, thus maintaining a high degree of 
equivocation. Moreover, it must be kept in mind that nowadays there is a lack of consensus on the 
definition of “metabolic health”. The one used for the term “metabolic” does not resolve the 
ambiguity concerning the etiologic causes of the disease, many “metabolic” conditions support, 
indeed, the development of the fatty liver disease. Finally, this definition does not include patients 
with liver steatosis in the absence of metabolic risk factors or significant alcohol consumption. 
These subjects seem to be younger and with more severe liver steatosis, which could represent the 
first expression of a metabolic syndrome 23.  The debate on which definition is the best applicable is 
still ongoing and further studies, research and validations will certainly be needed in order to decide 
on the basis of the evidence base medicine which definition between NAFLD and MAFLD is the 
best. Thanks to the evidence, it will therefore also be possible to overcome the clinical inertia that 





The NAFLD prevalence is progressively increased in recent decades, not only in Western countries, 
where it has doubled in the last forty years but also in Eastern ones 24–26. 
Although over the years, there have been several attempts to precisely define the magnitude of this 
condition, it is widely believed that the data provided only describe the tip of the iceberg, being 
NAFLD an often under-diagnosed disease. Undoubtedly, hepatic steatosis and steatohepatitis are 
pathologies characterized by a "silent" nature. In a non-negligible percentage of subjects, the most 
used and common bio-humoral tests (for example hepatic cyto-necrosis index) results fall within a 
normal range, and diagnoses of NAFLD occur accidentally 27. 
Worldwide, it is estimated that the median prevalence of NAFLD is around 20% (with a range 
between 6% and 35%), with wide variations within the different groups of subjects considered or 
according to the different diagnostic tool used 28. Several studies have shown that higher prevalence 
(varying between 45 and 58%) is observed in subjects of Hispanic origin than in Caucasians (33-
44%) and African-Americans (24-35%) 29,30. In the United States of America, in the general 
population, the prevalence of NAFLD would be 27-34%, while in obese subjects it would be around 
72-95% 27. The prevalence rates among subjects with type II diabetes mellitus would eventually 
reach 60-70% 8. Prevalence rates in Europe are also high and can vary from 8% to 35% (with a 
median of about 26%) 31. Parallel to what can be observed for obesity, the presence of a North-
South gradient is noted. This variability would not only be affected by the different diffusion of risk 
factors, but it could also be due to differences in the methods of diagnosis and definition of the 
disease in the various countries 25,27,31,32. In Italy in particular it is assumed that NAFLD affects 
about 25% of the general population 33. While in Greece, prevalence levels of around 45% have 
been established, while in Romania only 8% 27,34. Similarly to the data in North American countries, 
in Europe there is a similar higher prevalence of the disease in patients with diabetes (42.6-69.7%) 
24  and in those with metabolic syndrome (about 79%) 35. In Asian countries, it is estimated that the 
prevalence of hepatic steatosis is high (15-10%) and increasing in recent years 11,36. In China, rates 
of about 20% (6-38%) have been reported, in Japan about 15%, while in India they vary from 8 to 
30%, also based on the quality of the sources that are evaluated. Sri-Lanka, Hong Kong, Korea, and 
Indonesia show prevalence rates ranging from about 15 to 20% 37–40. The prevalence rates seem to 
be generally increasing in the countries located further east than in those of the south of the Asian 
continent, where they have been stable in recent years.  
Even regarding the incidence of NAFLD, there is a scarcity of data in the literature: it is estimated 
that it is around 10% and 5% respectively in the USA and Europe 41 and Asia 27.  
Finally, it is estimated that about 2-5% of the general population is affected by NASH 42. 
Most NAFLD diagnoses are made around the age of 40-50 43, with higher prevalence rates found in 
older patients.  
In the literature, on the other hand, there is no univocal prevalence in terms of gender: some studies 





As previously mentioned, the term NAFLD describes a broad spectrum of histopathological 
conditions that include simple steatosis, steatohepatitis, and even liver cirrhosis. Data extrapolated 
from multiple epidemiological studies show how, while hepatic steatosis would be characterized by 
an indolent course, steatohepatitis would have a more aggressive one with a greater risk of evolving 
into cirrhosis and developing a primary liver tumor. However, it is still not completely clear and 
defined whether these two conditions (NAFL and NASH) represent a continuum in the context of 
the same pathology or if they are two different pathologies that are not correlated with each other 42. 
Some authors recently suggested that NAFLD can be considered a dynamic disease, characterized 
by marked plasticity, in consideration of the possible fluctuations between steatosis and 
steatohepatitis over time 50.  
In 1998, Day and James proposed what was called "two-hit hypothesis" to explain the pathogenesis 
of NAFLD, according to which steatosis would represent the first pathological event that would 
then predispose the hepatic parenchyma to an increased susceptibility to a second insult, which 
would induce the development of hepatocellular damage, followed by inflammation and finally 
fibrosis 51. 
As more knowledge was gathered and analyzed, a new theory has emerged, according to which the 
development of steatohepatitis is the result of multiple etiological factors, which would act 
simultaneously and at several levels, and which would range from genetic predisposition to 
environmental factors, from dysmicrobism and overgrowth from the resident gut microbiota to the 
activity of the host's immune system52–54. 
Much remains to be understood and known about the concatenation of events that determine the 
evolution of simple hepatic steatosis into steatohepatitis, and the subsequent development of 
cirrhosis or hepatocellular carcinoma. 
The presence of a predisposing polygenetic substrate is well established (epidemiological studies 
and case-control have in particular highlighted how PLNPA3, TM6SF2, MBOAT7, GCKR, NCAN, 
LYPLAL1, SOD2, KLF6, HFE C282Y, and ATGR-1 are the most frequently associated with NASH) 
27,55 on which various conditions are grafted to concur to induce and feed a picture of insulin 
resistance (IR) and lipotoxicity, which, at the level of hepatocytes, induce an altered functioning of 
the endothelial reticulum system (ER) and the mitochondria. The production of reactive oxygen 
species and pro-inflammatory cytokines, together with hepatocyte cytonecrosis, activate 
inflammatory cells and fibrogenesis, pathognomic elements of NASH itself. 
An ever-increasing amount of data, obtained through genome-wide association studies (GWAS) 
conducted in large cohorts of extremely well-phenotyped subjects, has allowed us to demonstrate 
the pivotal role played by specific gene varieties in causing liver fat content, in the development and 
the progression of NAFLD 56. 
The rs738409 C>G single nucleotide polymorphism (SNP), encoding for the I148M variant of 
Patatin-like phospholipase domain-containing protein 3 (PNPLA3), warrant the higher percentage 
of genetic predisposition to NAFLD, leading hepatic fat accumulation and increased susceptibility 
to hepatic injury, without determining direct consequences on IR, glucose homeostasis, lipoprotein 
metabolism, or whole-body adiposity 57,58. In European populations, the frequency of this SNP 
allele is about 21%-28% 59. Individuals carrying this variant are more susceptible to developing the 
wide spectrum of liver disease characterizing NAFLD and primary liver cancer (even those 
presenting an early stage of liver disease), moreover, they are also at greater risk of liver-related 
mortality with or without NAFLD presence 56,60–63. The protein encoded by this gene, called 
Adiponutrin, is a 481 amino acid transmembrane bounded protein, localized in the endoplasmic 
reticulum and lipid membranes of hepatocytes and adipose tissue 59. It is normally expressed under 
glycemic and insulin stimuli in the hepatocyte, hepatic stellate cells, retinal cells and, during IR 
conditions, even in adipocytes. This protein acts as a lipase, it is involved in the metabolism of 
phospholipids, in triglycerides remodeling and has a retinyl-palmitate esterase activity, thus 
preventing fibrogenesis 64. The enzymatic loss of function induced by the I148M variant causes fat 
accumulation, facilitating lipotoxicity and, thought intracellular retinol esters retention, 
inflammation and fibrogenesis 60.  
The rs58542926 C>T SNP a missense mutation for the E167K variant of transmembrane 6 
superfamily member 2 (TM6SF2), encoded on chromosome 19p13.11, has been reported to be 
associated with variations in plasma lipid profile, cholesterol metabolism disorders, liver steatosis, 
and risk of progression NAFLD-HCC, representing a strong modifier of hepatic fibrogenesis 58,65,66. 
The TM6SF2 gene encodes a 351-amino acid transmembrane protein expressed in the liver and 
intestine in humans 67. The missense mutation is present in 7.2 % of Europeans, 4.7% Hispanics, 
and 3.4 % African Americans, resulting in a loss of function of the protein, that facilitates the 
reduction in the circulation of triglycerides-rich-lipoproteins and fat accumulation in the liver 
parenchyma, through compromised lipidation and maturation of chylomicrons in enterocytes and 
very-low-density lipoprotein (VLDL) in hepatocytes. 56,59,66,67. Secondary to the reduction of 
circulating serum lipids, TM6SF2 T alleles seem to confer protection against cardiovascular 
diseases 59,66. 
Another significant polymorphism involved in NAFLD predisposition and evolution, particularly in 
patients with European ancestry, is the rs641738 variant of the membrane-bound O-acyltransferase 
domain containing 7- Transmembranechannel-like4 (MBOAT7-TMC4) gene, localized on 
chromosome 19 68,69.  It is expressed in hepatocytes, hepatic stellate cells, and hepatic sinusoidal 
cells 70.  MBOAT7 encodes for a lysophospholipid acyl-transferase, a membrane-bound enzyme 
involved, thanks to its specificity for arachidonoyl-CoA as an acyl donor, in “Lands’ Cycle” of 
phospholipid acyl-chain remodeling of membranes pathways. This enzyme represents a fine 
regulator of free arachidonic acid 58,69,71. The rs641738 variant results in a lower protein expression 
and thus decreased enzyme activity and changes in plasma phosphatidylinositol species, which in 
turn result in increasing liver steatosis, inflammation, fibrosis, and development of HCC, even in 
patients without cirrhosis 56,67,69,72.  
A consistent amount of data has demonstrated the association between the variant of glucokinase 
regulator (GCKR) gene locus and fatty liver disease.  GCKR is involved in the regulation of the de 
novo-lipogenesis through the modulation of the influx of glucose in hepatocytes. The common 
missense P446L (rs1260326 C>T) variant encodes a loss-of-function of the proteins able to inhibit 
glucokinase in response to fructose-6-phosphate 67,71, which allow the uptake of glucose in the 
active hepatocytes and consequentially reduce the circulating fasting glucose and insulin levels 72.  
In this condition, liver steatosis results as a consequence of the increased production of malonyl-
CoA (involved in de novo lipogenesis) and by inhibition of fatty acid oxidation 58,67,68,72. 
Recently, exome-wide sequencing studies have demonstrated that the loss-of-function of 
rs72613567:TA in hydroxysteroid 17-beta dehydrogenase 13  (HSD17B13) confers protection 
against liver steatosis, and reduces the risk of devolving the whole spectrum of alcoholic non-
alcoholic liver diseases 56,67,71. The gene encodes for an enzyme, member of the short-chain 
dehydrogenase/reductase family, involved in the metabolism of fatty acids, sex hormones, and 
retinoids, expressed in hepatocytes and localized in the surface of lipid droplets 58,73. Even if the 
specific protein function is under investigation, it has been hypothesized that defective enzymatic 
activity induces a lower production of several pro-inflammatory lipid species (e.g. leukotriene B4) 
into the liver 71. Moreover, this SNP is associated with a reduction in PNPLA3 messenger rRNA 
expression in an allele dose-dependent manner, mitigating in this way PNPLA3 liver-damaging 
effects 58,74.  
Pathogenesis and evolution of NAFLD can be thus characterized as an extremely complex process, 
secondary to gene-gene and gene-environmental interplay, as well as a still not completely 
understood inter-organ crosstalk involving adipose tissue, pancreas, gut, and liver. 
The liver is an organ involved in the homeostasis of the entire organism by modulating not only 
glucose but also lipid metabolism. In obese subjects, the liver itself becomes a reservoir for lipids. 
Furthermore, in these subjects, the adipose tissue, which can be assimilated to a real organ with 
endocrine functions, undergoes processes characterized by inflammation and impaired functioning. 
This is caused by excessive accumulation of lipids in the adipocytes, which determines a condition 
of hypertrophy and induces their proliferation, which in turn favor and contribute to a condition of 
hypoxia, which predisposes to cell death 75,76. In this context, the altered adipocytes secrete pro-
inflammatory cytokines, such as TNF (Tumor necrosis factor or tumor necrosis factor) and 
chemokines (for example CC chemokine ligand 2 or CCL2) which attract and favor infiltration by 
macrophages, that, in turn, support and maintain the inflammatory milieu and IR status 77–79. 
Furthermore, there is a reduction in the production of adiponectin, an insulin-sensitizing and anti-
inflammatory hormone (stimulating the production of IL-10, through the enzymatic cascade of NF-
KB and inhibiting the release of TNFα, IL-6 and chemokines), and of visfatin (a central hormone in 
the biosynthesis of NAD)80 against an increase in the production of leptin. The latter would be 
characterized by possessing a lipostatic function, and therefore would have a protective effect 
against the development of NAFLD, but in conditions of IR, there would also be a consensual leptin 
resistance which would instead favor the onset of hepatic steatosis itself 81. IR also promotes the 
release into circulation by the adipose tissue of fatty acids, which are captured by the liver, thanks 
to transporters such as FATP5 and CD36, both up-regulated in conditions of obesity 27. The 
gluconeogenesis induced by IR itself contributes to inducing the development of hepatic steatosis; 
while hyperinsulinism and hyperglycemia through the pathways mediated by SERBP1 and 
ChREBP 27 determine the de novo synthesis of lipids, as previously described.  
The accumulation of lipid particles in the hepatocytes is a central event in determining a state of 
stress on the ER, which in turn favors and contributes to the maintenance of steatosis itself. This is 
possible on the one hand due to a reduction in the synthesis of apolipoproteins involved in the 
assembly and transport of VLDL (mediated by PERK or Protein Kinase RNA-like ER Kinase), and 
on the other following the induction of the SREBP1-SCAP complex and the activation of IRE1 
(Inositol Requiring Enzyme 1) and XBP1 (X-box binding protein 1), both of which represent two 
important stimuli for lipogenic sequence transcription 27. The alterations of the ER can also induce 
the death of the hepatocytes themselves. 
It has recently been shown that autophagy plays an important role in the homeostasis of hepatocytes 
and adipocytes 82. Autophagy refers to the process by which dysfunctional cell constituents are 
degraded and cellular energy deposits are maintained 27,82. In hepatocytes, not particularly rich in 
lipases, this mechanism allows the metabolism of the lipids themselves. Sing et at. have shown that 
its dysfunction characterizes hepatic steatosis and promotes the death of the hepatocytes themselves 
82. 
A further factor favoring NAFLD is represented by the alteration of the signaling pathway mediated 
by FRX (Farnesoid X Receptor), a receptor with which bile acids interact, which in physiological 
conditions would inhibit lipogenesis and the synthesis of fatty acids 27. 
As previously described, the dysmicrobism of the resident microbiota, induced by the 
characteristics of the constituents of the diet and by obesity itself, would favor not only the 
development of hepatic steatosis but also its progression. It was shown that patients who develop 
steatohepatitis presented a reduced proportion of Bacteroides and a higher ratio of Firmicutes-
Bacteroides 83. As previously described, this is associated with bacterial overgrowth, greater 
production of ethanol, reduced synthesis of choline, and an alteration of the intestinal mucosa that 
favor the passage of lipopolysaccharides into the circulation. All these factors contribute to 
determining and maintaining a pro-inflammatory state, with repercussions at the hepatocyte and 
systemic level. 
The LPS interaction with the receptors of the TLRs family present on the hepatocytes induces the 
inflammatory cascade mediated by PAMPs and DAMPs, which through the pathway induced by 
NF-KB involves the production of TNFα, the activation of the "inflammasome" responsible for the 
activation of various pro-inflammatory cytokines, such as IL1, which in turn contribute to 
maintaining active and feeding the inflammasome and the production of pro-inflammatory 
chemokines 27,52,84. This cascade can also be induced by the fatty acids themselves, through the 
interaction with the TLRs themselves but also through the induction of the inflammasome itself. 
Kupffer cells in response to pro-inflammatory cytokines contribute in turn to develop and 
perpetuate cell damage and the intra-hepatocytic inflammatory state, also following differentiation 
into monocytes with a marked inflammatory phenotype, called M127. 
Hepatocyte cytonecrosis also represents a further factor favoring inflammation and tissue damage, 
supported by multiple mechanisms, both receptor-dependent and independent. Among the former is 
caspase-induced cell apoptosis with consequent cell lysis, and necroptosis characterized by an 
inhibition of the caspase-mediated mechanism for which the signaling pathway that determines cell 
death is that secondary to PIP-PIP3-MLKL activation which induces hepatocyte membrane lysis. 
The receptor-independent mechanisms, on the other hand, are supported and induced by 
lipotoxicity, which determines a complex and extensive mitochondrial damage through the 
activation of JNK, which results in the production of ROS species, the depletion of ATP and 
therefore the activation of the caspases themselves. Last but not least, the activation of the 
inflammasome, again by fatty acids, can, as already mentioned, induce cell death through a 
mechanism "intrinsic" to the hepatocyte itself, also described as "pyroptosis" 27. 
A condition of prolonged and sustained inflammation and hepatocyte damage involves the 
activation of stellate cells that differentiate into fibroblasts. Cell death represents a direct and 
indirect stimulus, mediated by the release of cytokines, towards the development of hepatic fibrosis. 
This condition is induced, on the one hand, by the differentiation of stellate cells into 
myofibroblasts and, on the other hand, by the presence of soluble factors that would favor the 
survival of the former. Leptin would also stimulate the stellate cells themselves to produce collagen. 
Conversely, the inhibiting action carried out physiologically by adipokine, resistin and visfatin 
would be ineffective given the low circulating levels. 
Finally, it should be reported how recent studies have shown that hepatocytes that are characterized 
by ballooning phenomena, that is those hepatocytes that have started a process that ultimately 
results in the death of the cell itself, and that characterize the pictures of NASH, produce a protein 
that would favor tissue fibrosis, called "sonic hedgehog". This polypeptide would stimulate 
cholangiocytes to produce osteopontin which would act in a paracrine manner on stellate cells 
favoring the deposition of collagen 85,86. 
The cell death of hepatocytes triggers inflammation, fibrosis and even the onset of heteroplasia. 
Certainly, further studies are needed, both in vivo and in vitro, to better define all the mechanisms 
involved in the development and progression of this complex pathological. Also, in order to be able 






According to the last guidelines, the diagnosis of NAFLD is based on the presence of the following 
elements: (a) findings of hepatic steatosis through histological or radiological investigations; (b) the 
absence of alcohol consumption exceeding 20-30 g/day in women and men respectively; (c) the 
exclusion of conditions that can lead to the development of secondary steatosis 2,8,87,88. 
In fact, given the lack of surrogate diagnostic markers of NAFLD, it is essential to perform a careful 
diagnostic work-up aimed at excluding other causes of liver disease: from viral to autoimmune 
forms, from hoarding to drug-induced or toxic forms. However, it should be remembered that 
hepatic steatosis is often associated with these pathologies, in particular, this has been shown in the 
course of HVC related hepatitis, where the concomitance of the two conditions has been shown to 
reduce the response to treatments involving the use of interferon 89. 
The dosage of cytonecrosis indices is not useful for diagnostic purposes, since in 50-80% of patients 
with NAFLD the dosage of transaminases is within the normal range. The dosage of hyaluronic acid 
and other fibrosis markers is high in patients with a degree of fibrosis superior to F3, but these 
indicators are not routinely measurable in all laboratories. The finding of alterations in the platelet 
count, hypoalbuminemia, marked alteration of direct and indirect bilirubin or an increase in 




The gold standard for the diagnosis of NAFL or NASH is still represented by hepatic needle biopsy, 
as these two histopathological entities are different and not otherwise differentiated from each other. 
Nevertheless, this procedure is not free from risks and limitations. First of all, it is an invasive 
procedure, with possible complications such as bleedings, infections or bileo-puncture resulting in 
peritoneal resentment. Furthermore, it is also expensive. It may also no be representative, since the 
sample taken represents only a small percentage of the entire organ, also in consideration of the fact 
that the disease does not affect the parenchyma uniformly. Moreover, the sampling may also be 
affected by sampling errors or the frustule may be unsatisfactory. Finally, the assessment is 
burdened by a wide operator-dependent variability, related to the experience levels of the different 
anatomopathologists conducting the examinations. It should be remembered that only a limited 
percentage of NAFLD patients have steatohepatitis, which means that, to diagnose this condition, 
the number of subjects to be biopsied is much higher than those who would need it. Therefore, it is 
possible to state that liver needle biopsy is a poorly suited tool as a diagnostic test for NASH. In 
light of all these considerations, a biopsy is currently indicated in patients considered most at risk of 
developing NASH with fibrosis or in those with concomitant chronic liver diseases 7,8. 
The histopathological examination in the case of NAFL shows the presence of hepatic steatosis 
greater than 5%. In the case of NASH, on the other hand, in addition to steatosis, the presence of 
"balloon-like" degeneration and lobular inflammatory infiltrate is noted. Around the central veins, 
in the region known as zone 3, pathognomonic elements such as Mallory's hyaline bodies and the 
presence of peri-cellular fibrosis are observed. Some atypical elements have been described in 
morbidly obese subjects or children, such as periportal steatosis in zone 1, the absence of ballooning 
or Mallory's bodies, and greater degrees of fibrosis or portal inflammation 2,90–92. 
Over the years, various histopathological classifications have been proposed for NAFLD: 
Matteoni’s, Brunt’s, the NAFLD activity score (NAS), and the SAF score 46,93–95. In 1999, Matteoni 
et al. proposed a dichotomous classification that distinguished NASH and non-NASH, in particular, 
it identified: a type 1, or subjects with simple steatosis; a type 2, in which steatosis and lobular 
inflammation were noted; a type 3, who presented steatosis associated with hepatocellular 
ballooning; and a type 4, which in addition to the typical characteristics of the third group showed 
the presence of Mallory's bodies and fibrosis. Those who presented a picture compatible with the 
first and second types were characterized by an indolent and benign course compared to those who 
fell into the last two groups 46. The latter was described as NASH, while the others, antithetically, as 
non-NASH or NAFLD. This classification, however, presents a considerable bias as it does not 
provide an assessment of the severity or pattern of NASH: that is, it does not give information on 
the degree of steatosis, on inflammation, on the localization of these alterations (whether for 
example they are observed at the lobular or periportal level ), as well as on the degree of fibrosis 2. 
In the same year, a semi-quantitative system was proposed by Brunt and colleagues, to define the 
grading and staging of liver disease. This classification applied only to patients diagnosed with 
NASH 93. 
Finally, in 2005, the NASH Clinical Research Network Pathology Committee developed and 
validated a histological scoring system based on the Brunt classification: the NAS. This semi-
quantitative tool has been proposed as a reference classification for evaluating responses to any 
treatments or disease progression in clinical trials. It is characterized by the advantage of being 
independent of the experience of the pathologist who evaluates the liver frustule 96. But it is not a 
tool to be used for diagnostic purposes. It was found that the presence of a typical histological 
picture for steatohepatitis may not coincide with a NAS score that could classify it within the 
NASH group, so it is recommended not to use it categorically for the diagnosis of NASH 97. 
The NAS is addressed to the entire spectrum of NAFLD and it is applicable in both adults and 
pediatrics 2. The score, between 0 and 8, is linked to the sum of the single values that describe 
steatosis (from 0 to 3), the presence of inflammatory lobular infiltrate (from 0 to 3) and ballooning-
forms degeneration (from 0 to 2) (figure 1). A score above 5 is diagnostic of NASH, scores below 3 
are "non-NASH", while those between 3 and 4 are defined as borderline. For what concerns 
fibrosis, stage 1 is described as the situation in which this affects the peri-sinusoidal region in zone 
3. In particular, in the perivenular area, this can be mild 1A or dense 1B, while 1C is defined as the 
case of portal fibrosis without fibrosis perisinusoidal. Stage 2 is characterized by perisinusoidal and 
portal/periportal fibrosis. The presence of fibrin bridges is typical of stage 3, while the presence of 
cirrhosis identifies stage 4. Cohort studies have shown that the degree of fibrosis is an independent 
predictor of hepato-related mortality. Consequently, the precise quantification and determination of 
the degree of fibrosis represent a prognostic element of fundamental importance 98–100 (figure 2 and 
tables 2 and 3). 
Bardossa and co-workers proposed and validated a score and a diagnostic algorithm aimed at 
histopathologically categorizing hepatic lesions in the NAFLD 95. The SAF score aims to overcome 
the main limitations attributed to the NAS score. It has been argued that it appears as an excessively 
artificial classification, that it describes borderline pictures poorly, and that it is characterized by a 
large gray area (values between 3 and 4) 92. The SAF score, as a semi-quantitative model, evaluates 
the degree of steatosis, with a score ranging from 0 to 3, the degree of activity of the disease 
(combining the degree of lobular inflammation and ballooning, providing a result between 0 and 4) 
and the stage of fibrosis (0 to 4). Thanks to the separate description of the main histopathological 
characteristics, it is a useful tool for comparing biopsy samples and their evolution over time, both 
in the context of trials and in common clinical practice. Finally, it allows to identify those patients 
who have blurred pictures or not univocal categorization 95. The evaluation, in patients with hepatic 
steatosis greater than 5% (i.e. with a degree of steatosis greater than 1), of the level of ballooning 
and lobular inflammation allows, thanks to the FLIP diagnostic algorithm proposed by Bedossa 
himself, to classify in a dichotomous manner the liver biopsies in steatosis and steatohepatitis 101 
(figure 3 and table 4). 
Many authors agree in recognizing the usefulness of all these classification tools but underline that 
these scores cannot replace the analytical description made by the pathologists themselves, who 
make a diagnosis based on the complex evaluation of each element found during the histological 
examination. Although these reports may appear subjective and less precise, the evaluation of the 
regression has shown that, if compared to the scores, these first appear to be the most powerful 
diagnostic tools 92,97. 
Recently Nacimbeni et al. demonstrate, in a cohort of 140 consecutive patients, that FLIP/SAF 
classification allows to identify the different disease categories with a good match with entities of 
different clinical and biological severity. Furthermore, they observed the presence of a strong 
association between the histological definition of steatohepatitis activity and the amount of fibrotic 




Ultrasound of the abdomen is the main method currently used for a qualitative assessment of the 
hepatic parenchyma and consequent identification of a steatosis picture. This is due to the 
characteristics of this method: non-invasive, easily accessible, inexpensive, and able to provide 
useful information on the characteristics of the hepatic parenchyma, the biliary tract, the size and 
vascularity of the organ. 
The presence of hepatic steatosis is diagnosed ultrasonographically based on the finding of 
increased contrast following the comparison between the echogenic characteristics of the renal 
cortex and the hepatic parenchyma, the finding of a hyperechoic or "brighter" liver, posterior 
attenuation, and a sort of blurring of the main hepatic vessels 103,104. Nevertheless, the diagnosis on 
an ultrasound basis has several limitations: first of all, ultrasound is operator dependent and, 
therefore, it is affected by the experience and subjective evaluation of the clinician or radiologist 
who performs the examination; it is also characterized by having a reduced sensitivity in identifying 
pictures of modest steatosis; finally, it is not able to quantify it 105,106. 
Both computerized axial tomography (CT) and nuclear magnetic resonance (MRI) seem to offer 
greater degrees of objectivity and greater sensitivity in terms of quantification of steatosis. Both, 
however, are more expensive and not as universally, easily and readily accessible, especially MRI. 
Moreover, CT is burdened by the risk resulting from exposure to ionizing radiation and is 
characterized by low sensitivity in cases of mild/moderate steatosis, as well as of not being 
diagnostic in patients with hemochromatosis. The evaluation of hepatic steatosis by CT uses the 
determination of a hepato-splenic attenuation ratio lower than 0.9 2,107,108. 
It should also be remembered that in conditions of advanced fibrosis both ultrasound and CT see a 
further reduction in their diagnostic sensitivity, this following the interference caused by the fibrosis 
itself 107. Similarly, in the case of marked steatosis and obese patients, the ability to identify fibrosis 
is reduced with both methods 2. 
Finally, it should be emphasized that none of these procedures allows us to identify NASH or 
distinguish it from NAFL. 
 
Other non-invasive methods: Fibroscan®, CAP, ARFI e RET. 
 
Over the years various non-invasive and easily repeatable methods have been proposed in order to 
obtain an estimate of hepatic fibrosis by evaluating the stiffness of the parenchyma itself; although 
severe obesity and the presence of marked tissue inflammation may affect the accuracy of the 
results thus obtained. 
The FibroScan® (EchoSens, Paris, France) is an instrument similar to an ultrasound with a probe 
that functions as an ultrasound transducer and vibratory pulses. In particular, this transmits a 
vibration wave of medium amplitude and low frequency (50 Hz), from the body surface, at the level 
of the intercostal spaces, to the underlying hepatic parenchyma, in order to obtain an estimate of the 
elasticity of the latter, by the analysis carried out on a section of about 4 x 1 cm at a depth of about 
2.5 cm. The vibration induces an elastic wave that propagates in the tissue at a speed that is 
proportional to its elasticity (E = 3ρV2 where E represents the elasticity, ρ the density which is 
constant for a given tissue and for the liver is = 1, V the propagation speed of the wave). Therefore, 
the less elastic the parenchyma, the greater the speed measured. The stiffness, expressed in kPa, 
represents the median obtained following ten measurements. To be considered reliable, the data 
must have an IQR (variability of the measurements performed) which must not exceed 30% with 
respect to the median, and a "success rate", i.e. the number of useful measurements, which must be 
at least 60% with respect the total number of acquisitions made. The results are highly reproducible 
and can be repeated over time, without exposing the patient to peri or post-procedural risks, to 
invasive procedures or using ionizing radiation or contrast media 109. Various studies, carried out 
with the standard probe M, have attempted to define the reference values for the different degrees of 
fibrosis. These vary according to the etiopathogenesis of liver disease. For NAFLD values between 
6.6-7.8 kPa fall within grade F2; 7.1-10.4 kPa describe a stage equal to F3, while 10.3-22.3 kPa 
correspond to an evolution now in terms of cirrhosis (F4) 110–112. The cut-off values for each degree 
of fibrosis vary according to the studies examined 109.  Obesity, frequently present in patients with 
NAFLD, causes failures of between 5 and 9% in acquisitions by FibroScan® in the measure of 
stiffness 108,113, with a reduction in reliability of about 23% 111. This is probably attributable to the 
interference caused by excess subcutaneous adipose tissue 114. To overcome this drawback, a probe 
called XL has been developed, which can be used in obese subjects. 
In the literature, conflicting data also emerged on the possible interference caused by steatosis and 
necro-inflammation on the reliability of the results provided by FibroScan® in this subset of 
patients 110,111,115. 
An innovative and promising application of FibroScan® is based on the measurement of the degree 
of acoustic attenuation as the ultrasound passes through the parenchyma, allowing the calculation of 
the CAP (controlled attenuation parameter). This parameter, expressed in dB/m, seems to correlate 
with the degree of hepatic steatosis. However, the lack of defined reference levels and the influence 
of various variables such as the presence of diabetes mellitus, BMI and etiology, limits the use of 
CAP in daily clinical practice. Furthermore, in about 15% of patients the results obtained by CAP 
do not coincide with the histological data 116. Although the supporters of the method underline that 
the CAP allows to analyze a tissue sample about 100 times higher than the histologically evaluable 
one and that therefore this discrepancy could be attributed to the intrinsic limits of the biopsy 
sample rather than to the CAP itself. Until now, however, no reliability criteria have been 
established for CAP measurements. Kars et al. have recently proposed as cut-offs: 248, 268 and 280 
dB / m for S0, S1 and S2, respectively 116.  However, further studies are necessary to better 
investigate the underlying mechanisms, as well as to validate the method and the reference limits in 
larger populations. 
The ARFI or Acoustic Radiation Force Impulse devised by Siemens is applied to Acuson S2000® 
(Siemens AG, Erlangen, Germany) 117, during the B-mode examination, it studies the elasticity of a 
portion of the liver parenchyma identified by a ROI (Region of interest). The tissue identified 
through the ROI is mechanically excited using acoustic pulses to induce localized tissue 
displacements, secondary to wave propagation. This in turn generates a wave, called shear wave or 
shear wave, which is followed using ultrasonic correlation methods. Its propagation speed is then 
estimated by evaluating the lateral displacement time in a defined spatial area. The study is 
performed on the right lobe of the liver, 2-3 cm below the hepatic capsule. The median of ten 
suitable acquisitions is expressed in terms of shear wave velocity (SWV) in m/s. SWV is considered 
proportional to the square root of the elasticity of the liver parenchyma 114. Data with an IQR/mean 
ratio of over 0.3 are considered to be affected by excessive variability and not considered reliable. 
The limit values of the various degrees of fibrotic evolution in NAFLD vary considerably in 
different papers 41–44. The cut-off values reported for F2, F3 and F4 were 1.165, 1.48-2.06 and 
1.635-1.9 m/s respectively. The limits proposed to discriminate NASH from NAFL are 1.105 m / s 
(F1) 44 or 1.3 m/s (identifying steatosis with inflammation, without fibrosis) 118. From the literature 
data it would seem that obesity or various degrees of liver fibrosis or ballooning do not affect the 
results obtained. Yoneda et al. described how there is a variation in velocities detected between the 
groups with different inflammatory activity, even if this does not start gradually. Thus, it could be 
assumed that steatosis probably decreases SWV while inflammation increases it 119. Comparing the 
diagnostic accuracy of the two procedures, no statistically significant differences were identified 
between ARFI and FibroScan® for the diagnosis of fibrosis, cirrhosis and steatohepatitis. So that, in 
the event that reliable data are purchased, both methods can be considered reliable. 
On its ultrasound systems, the Hitachi company has developed real-time elastography (RTE), which 
provides information on the physical characteristics of tissues using the normal ultrasound probe. 
During the execution of the B-mode study, the elastic properties of a portion of the parenchyma are 
studied, identified through the ROI. The ROI consists of approximately 30,000 elements. During 
the compression induced by the probe, the displacement of each element is measured. In rigid 
fabrics, the amount of displacement is low, while in stretch fabrics it is high. The calculation of the 
elasticity distribution of the fabrics is performed in real time and the results are displayed as colored 
images with the conventional image B in the background. The final result is based on data obtained 
from ten reproducible measurements. To date, there are few studies evaluating the applicability of 
RTE in subjects with NAFLD, so further research is needed to define the diagnostic cut-offs for 




The term NAFLD, in general clinical practice, is appropriately used for the diagnosis and 
management of a wide variety of patients and, in this context, serum biomarkers, useful tools for 
identifying the degree of fibrosis, can be exploited to in turn for the identification of NAFLD in 
patients with fibrosis or cirrhosis 2. 
 
CK-18, FGF-21, CBP. 
 
Hepatic steatosis is frequently accompanied by a slight to moderate increase in the serum level of 
aminotransferases and changes in gamma-glutamyl transferases (γGT). These alterations, in the 
most favorable condition, allow to identify only those at greater risk of being affected by NAFLD, 
and who therefore require further diagnostic tests. However, as previously mentioned, they are 
imprecise indicators and therefore should not be the only tools used in clinical practice 120. The 
dosage of hepatic cytonecrosis indices, in particular ALT, can be particularly misleading, appearing, 
in a not limited percentage of patients, even in the presence of a histological alteration, within the 
normal limits 121,122. The diagnostic accuracy of ALT alteration, estimated in patients with NASH, 
is particularly low, around 40% 122,123. 
In light of these limitations, in recent years many authors have pursued biomarkers able to predict 
the risk of evolution of NAFL or the presence of hepatic fibrosis. An ideal serum marker should 
certainly be easy to measure, accurate and reproducible, inexpensive, and immediately accessible 
and available. It should allow to favor discrimination between the various stages of the disease and 
to follow it over time and evaluate the effectiveness and response to a therapeutic treatment. 
Generally, while most biomarkers and scoring systems are similar in terms of accuracy for 
identifying advanced fibrosis conditions, their accuracy is limited in mild fibrosis cases 2,122. The 
diagnostic accuracy of various proteins was studied, released into the circulation as a consequence 
of oxidative stress, inflammatory processes, hepatocyte apoptosis or in response to alterations in 
lipid metabolism. These, in a limited number of studies, were evaluated both individually and in 
combination with each other to evaluate their diagnostic accuracy. 
Cytokeratin 18 (CK-18) is one of the major intermediate filament proteins contained in hepatocytes. 
Following apoptosis, fragments of CK-18, whether or not subjected to cleavage by caspases, called 
M30 and M65 respectively, are released into the circulation 122. The assay of both fragments was 
found to be accurate in discriminating between NASH and NAFL, with AUROC values of 0.82 
(95% CI, 0.79-0.85) for M30 and 0.80 (95% CI, 0.76-0.83) for M65 122. The normal limits 
identified in the various studies for M65 are between 243.8–790 U / L (0.62–1 sensitivity and 0.65–
0.89 specificity), while for M30 they are 121.6–380.2 U / L (0.60–0.95 sensitivity and 0.60–0.97 
specificity) 122. 
The fibroblast growth factor 21 (FGF-21) is instead a hormone secreted by hepatocytes that has 
been found to have beneficial properties on lipid metabolism and hepatic steatosis 122. Several 
studies have shown how the serum levels of this marker are associated with the hepatocyte content 
of lipids, especially in patients with moderate hepatic steatosis 122. In the meta-analysis performed 
by He and co-workers, the standardized mean difference is greater in patients with NASH than in 
those with simple hepatic steatosis (MDS 1.47, 95% CI, 0.13–3.07 vs SMD 1.12, 95% CI 0.27–
1.97), thus allowing for the assumption that this marker can be used in the diagnosis of 
steatohepatitis. The authors underline that further ad hoc studies are needed to better define the 
sensitivity and specificity and evaluate the AUROC 122. Some researchers, in consideration of the 
complexity of the pathophysiological process underlying the development and evolution of 
NAFLD, have suggested resorting to the use of a combination of two or more serum markers, to 
provide more precise information about the risk of evolution. of the pathology. 
For this reason, the combined biomarker panel (CBP) has been proposed, which also includes the 
assay of CK-18 and FGF-21 among others. CBP would have greater diagnostic accuracy than that 
possessed by single markers with an AUROC equal to 0.94 (95% CI, 0.92-0.96), demonstrating a 
better discriminatory capacity between NASH and hepatic steatosis, with a sensitivity and 
specificity of 0.92 respectively ( 95% CI, 0.88-0.95) and 0.85 (95% CI, 0.72-0.92) 122. 
In conclusion, the data available up to now in the literature would seem to show that increased 
serum levels of these markers are associated with an increased risk of developing NASH. The 
combination of the latter allows to optimize the ability to distinguish between simple hepatic 
steatosis and hepatitis. 
Although many papers have evaluated the performance of these markers, there is no consensus on 
which of these has the best diagnostic power. 
Furthermore, the marked heterogeneity that characterizes many of the published research makes it 
difficult to compare them, so that it is mandatory to expand the number of studies, their sample size, 
and make them homogeneous to optimize and improve research on this subject. 
Tests were also proposed that combine clinical and other information extrapolated from biohumoral 
data to predict the risk of NAFLD/NASH of the individual patient, offer a stratification of the same 
and provide indications for any second-level assessment. These include the NAFLD fibrosis score 
120,124, the FIB-4 125, the FibroTest, the Fibrometer, and the Enhanced Liver Fibrosis (ELF) score 
120,125,126. The first two can be calculated about platelet counts, albumin levels and ALT. FibroTest, 
Fibrometer and ELF score are commercially available tests. Even these non-invasive methods 
require further studies and validation and can be useful for identifying patients deserving to undergo 
liver needle biopsy which to date remains the only reference method to distinguish NASH from 
simple steatosis. 
 
Squamous cell carcinoma antigen (SCCA)/SerpinB3 
 
Serpine isoforms B3 and B4, also known as squamous cell carcinoma antigen 1 and 2 (SCCA1 and 
SCCA2) belong to the ovserpine/clade B serpin family. They are protease inhibitors implicating in 
many control processes of cellular homeostasis and as many biological functions 127. 
More than 1500 members of serpins have been identified in plants, invertebrates, bacteria, and 
viruses 128,129. Ovserpines are typical of vertebrates, fish, and mammals, and can be considered an 
evolution in two gene loci of a single ancestral gene. Serpins inhibit proteases by a suicidal 
inhibition mechanism. They possess a marked specificity for their target proteins, linked to the 
differences in the sequence of the site of action, which allows them to be adequately identified as 
proteases. These determine the cleavage of a specific domain inducing an alteration of the form of 
the ovserpine which therefore irreversibly inhibits the protease itself 127. 
Isoforms B3 and B4 evolved by acquiring inhibitory activities against cysteine proteases 130,131 
The two genes encoding the two isoforms of serpin are located on chromosome 18, in the q21.3 
region of 600 kb 132, together with at least four other genes encoding serpin variants. These two 
almost identical genes are distributed in tandem on the chromosome (head-tail pairing): the gene for 
SerpinB3 is located in the most proximal portion to the centromere, while that for SerpinB4 is 
located more distally near the telomere region. This peculiar arrangement suggests that they are the 
result of a duplication of a single common ancestral gene 133. Even if characterized by a high 
homology of their amino acid sequences, they demonstrate similarities and different substrates 134: 
SerpinB3 inhibits cysteine-proteases (papain, cathepsin S, K and L) 135, while SerpinB4 acts on both 
serine protease (cathepsin G) and cysteine proteases (Der p1 and Der f1) 129,131,136. The peculiarities 
of the reaction site (RSL) of each serpin is responsible for the different specificities of action. Only 
7 out of 13 amino acids coincide, or 54% 137. 
In vivo, it is still not entirely clear what their role at the physiological level is, nor what the 
mechanisms underlying the regulation of their different expression are 129; this is partly because 
they are co-expressed in both healthy and pathological tissues and that they have high percentages 
of homology both at the level of the messenger RNA sequence and when the amino acid sequences 
that constitute them are evaluated 138.  
Both isoforms are expressed by the spiny and granular layers of the normal squamous epithelium in 
a variety of organs including tonsils, tongue, esophagus, cervix, vagina, major airways, and 
Hassall's corpuscles in the thymus 139. 
Regarding their role in normal tissues, it has been postulated that the two isoforms play a protective 
role against bacterial and viral proteases 140, mast cell chymases 141 and that they can play a role in 
preventing the apoptosis of the stratum corneum cells. SerpinB3, in particular, is normally 
expressed in squamous epithelia such as the epidermis, cervix, bladder, esophagus, tonsils, airway 
epithelium, as well as in the prostate, testicle, or thymus 138. 
In the course of chronic inflammatory processes involving the skin (as in the case of atopic 
dermatitis and psoriasis) and the respiratory tract (asthma, chronic bronchitis, and tuberculosis), 
marked levels of expression were detected 142–145, further supporting the hypothesis its involvement 
in cellular homeostasis and the modulation of inflammatory response 138. Turato and colleagues 
have shown that chronic hepatocytic damage can induce the expression of SerpinB3 and TGF-β1. 
The same serpin-stimulated antiprotease activity would, in turn, be involved in the induction of the 
same TGF-β1, acting as a modulating protein. The combination of these two stimuli would favor 
the development of hepatic fibrosis 146. 
A further stimulus capable of inducing the transcription, synthesis, and release of SerpinB3, 
mediated by HIF-2α and by the presence of reactive oxygen species, appears to be hypoxia, as 
described by Cannito et al. 147. 
Novo and coworkers recently demonstrated, in an in vitro study, that during chronic liver diseases 
the hepatocytes release SerpinB3, which contributes to parenchymal fibrogenesis through the 
activation of myofibroblast-like hepatic stellate cells (HSC/MFs) 148. 
The hyper-expression of SerpinB3 has also been observed in the course of various heteroplastic 
lesions: particularly in those of epithelial origin 139,149, in adenocarcinoma of the lung, breast, and 
pancreas, as well as in hepatocarcinoma 150–153. The degree of expression seems to correlate with the 
development of tumor disease and is a useful predictor of the stage of the disease and its response to 
therapy 138,154,155. SerpinB3 is involved in various stages of the oncogenic process, acting as an 
authentic oncoprotein 138. It favors the survival of neoplastic cells by interfering with cellular 
apoptotic processes, it promotes cell proliferation and migration, and it is involved in the processes 
of intrinsic resistance to chemotherapy 138,156–158. 
It is known that the loss of homeostasis between proteases and its inhibitors has repercussions on 
mobility, invasiveness, proliferation, and finally on cell death itself 159. On the one hand, Serpin B3 
plays a role in the regulation of proteolytic processes (important junctions in the development of the 
tumor phenotype), on the other hand it is able to protect the neoplastic cell from apoptosis induced 
by various stimuli 160,161 by inhibiting the activity of caspase-3 160, and, finally, at the same time can 
promote cell proliferation 158. 
Furthermore, it has been shown in vitro that SerpinB3 inhibits the release of cytochrome c from the 
mitochondrion, thus suggesting its influence at the level of a bid or bcl-2 activation 162. 
SerpinB3 can induce the production of pro-inflammatory and pro-tumor cytokines such as 
interleukin 6 (IL-6) 157,163. It is an important mediator of RAS-induced pro-inflammatory cytokine 
production, such as interleukin 8 (IL-8), granulocyte-macrophage colony-stimulating factor 
(Granulocyte-Macrophage Colony-Stimulating Factor or GM-CSF) and platelet factor 4 (PF4) also 
known as chemokine CXC motif ligand 4 or CXCL4 138. It also increases the expression of c-Myc 
164. These processes are involved in neoplastic invasiveness and the epithelium-mesenchymal 
transition (EMT) 165 (figures 4 and 5). 
Another mechanism favoring tumor growth is linked to the ability of this serpin to block the 
intratumoral translocation of Natural Killer (NK) cells 166. 
The altered pro-apoptotic pathway has also been similarly shown in hepatocarcinoma, where it is 
precisely inhibited 167, this could be at least partially linked to SerpinB3. The overexpression of this 
serine would negatively modulate programmed cell death, favoring the immortalization of 
neoplastic cells. 
SerpinB3 has been detected in the cytoplasm and at the nuclear level of tumor cells, and in the 
serum of patients with squamous-cellular tumors. Moreover, concentrations of this serpin in the 
form of circulating immune complexes composed with immunoglobulins of the IgM isotype have 
also been recently detected in the serum of subjects affected by hepatocellular carcinoma. In this 
condition, an imbalance in the ratio of serpinB4-IgM and serpinB3-IgM concentrations was 
detected 129,150. 
This complex was also detected in patients with chronic hepatitis and/or liver cirrhosis, but not in 
healthy controls, and any case at lower concentrations than those circulating in patients with HCC. 
These considerations have led to the hypothesis that SCCA-IgM may represent a useful diagnostic 
marker for cancer and advanced liver disease 129,168,169. 
Martini and co-workers finally described how elevated plasma levels of SCCA-IgM in patients with 
HCV-related liver disease are significantly associated with the histological presence of a NASH 
picture. 
Because the SCCA-IgM immune complex was mainly detected in the serum of HCV positive 
subjects, compared to HCV negative controls, it can be hypothesized that a viral infection causing 
cytolytic damage may induce the expression of serpin or that the presence of SCCA-IgM is linked 
to the presence of steatohepatitis itself, regardless of the etiology of chronic liver disease 170. 
PROGNOSIS AND COMPLICATIONS 
 
Simple steatosis can progress to steatohepatitis 43,46,54,171–173. The greatest predictors of risk are 
represented, as previously mentioned, by advanced age, male sex, genetic and metabolic factors. 
The rates of disease progression are lower than those observed in other liver diseases such as in the 
case of HCV related 174. It is estimated that progression from steatosis to cirrhosis may take about 
57 years, while in the case of steatohepatitis about 24 years 173.  
Fibrosis by itself is a strong predictor of hepato-related mortality in NAFLD patients 120,171. 
Obesity, type II diabetes mellitus, hypertension, premature menopause, increase in intima-media 
thickness (IMT) at the carotid level, whether or not accompanied by atherosclerotic plaques, are all 
elements associated with fibrosis progression and cirrhosis development in subjects with liver 
steatosis 175–177.  In particular, the presence of type II diabetes mellitus and steatosis predicts the 
development of clinically significant hepatic fibrosis 178. 
El-Serag et al. estimate that NAFLD accounts for the 30-40% of HCC worldwide cases 179. 
Younossi and colleagues in a metanalysis published in 2016 calculated HCC incidence in subjects 
with NAFLD to be 0.44 per 1000 person-years. However, for subjects who develop NASH, the 
incidence of HCC increases to 5.29 per 1000 person years 26. Pathogenesis of primary liver tumor in 
NAFLD is not completely understood, since multiple mechanisms are involved: as already 
mentioned, the presence of specific genetic polymorphisms plays a central role, together with 
environmental factors, obesity, and type II diabetes mellitus. Low-grade chronic inflammation, 
insulin resistance, hyperinsulinemia, increased levels of insulin growth factor, fat accumulation 
inducing lipotoxicity, mitochondrial dysfunction, stellate cell activation, increased levels of LPS 
due to gut microbiota alteration, all represent the main actors that interplay together to activate and 
produce inflammatory cytokines (i.e. TNFa, TGFb, IL-6, and IL-17), reactivate oxygen species, 
deregulate phosphatidylinositol-3-kinase (PI3K) and Akt, and finally cause genomic instability 
through pro-oncogenic signaling activation (i.e. segregation defects, and alterations in the DNA-
damage-response pathways 180–182. Individuals with NAFLD are at an increased risk of developing 
HCC even in the absence of significant cirrhosis or fibrosis. Even though in these individuals HCC 
is characterized by larger sizes and poorly differentiated 180,181, to date there is no possibility of 
accurately predicting the risk of developing hepatocellular carcinoma in patients who do not have a 
histological liver specimen characterize by a fibrosing evolution. Therefore, there are currently no 
strategies or protocols for surveillance or monitoring of these patients. It follows that the disease is 
often diagnosed late, often when eradicating treatments are no longer possible, with negative 
consequences in terms of prognosis and survival 183–185.  
However, the main cause of mortality in these patients remains cardiovascular diseases. A recent 
meta-analysis demonstrates that subjects with NAFLD have a greater risk of developing fatal and 
non-cardiovascular events than those not affected 186. This according to a gradient that proceeds 
parallel to the severity of NAFLD itself. Thriving literature has shown how this condition is also 
associated with myocardial remodeling, favoring the development of functional and structural 
myocardiopathy, correlated on the one hand with the development of valvulopathies (from 
aortosclerosis to calcification of the mitral annulus) and on the other, to the increase in the 
incidence and prevalence of permanent atrial fibrillation 187–192. NAFLD is also associated with QTc 
elongation 193,194 and with an increased prevalence of detection of ventricular arrhythmias with 
Holter electrocardiographic monitoring, 195. Moreover, preliminary data would seem to suggest an 
association between NAFLD and an increase in the risk of re-hospitalization one year after an 
episode of heart failure 196,197. 
Finally, it should be noted that extensive epidemiological studies reveal the existence of an 
association between this condition and the onset of other types of heteroplasias, such as colorectal 
cancer 198,199. So much so that mortality from neoplastic diseases ranks second among the causes of 
death in subjects with NAFLD. Other associations have been reported such as cancers of the 
pancreas, esophagus, stomach, kidney, prostate, lungs, and breast 198,200–202. These data are all 
preliminary and while noting a close association with the condition called "diabesity", further 
studies deserve observations to validate any correlation with NAFLD 120. 
AIMS OF THE STUDY 
 
NAFLD, over the last two decades, has become the most common liver disease affecting about 25% 
of the general population worldwide 182. At the same time, it has also become the main and 
emerging cause of HCC in patients with and without cirrhosis, favored by the obesity pandemic and 
the increased incidence of diabetes and other characteristic elements of the metabolic syndrome 
(MetS).  
The lack of NAFLD awareness, due to the absence of specific symptoms and signals, exposes 
unknowingly affected patients to a high risk of disease progression and late diagnosis of its 
complications.  
Current guidelines 7 recommend screening for features of MetS in all individuals with steatosis, 
independently of liver enzymes levels, and screening all subject with persistently abnormal liver 
enzymes (level A1) for NAFLD. Furthermore, for individuals with obesity or MetS, an evaluation 
of liver enzymes and/or an ultrasound study of the liver (level A2) is recommended as part of 
routine work-up screening for NAFLD. For patients with age> 50, T2DM and MetS (which qualify 
them as high risk) it is advisable to investigate the presence of advanced disease (NASH with 
fibrosis) (level A2) 7.  
Liver biopsy, despite sampling variability limitations and procedural risks, still represents the gold 
standard for the diagnosis of NASH, and it is the only tool currently available to distinguish 
between pure fatty liver and steatohepatitis.  
Over the years, many authors have searched for surrogate markers of hepatocyte damage and 
fibrosing evolution to identify patients at greater risk of disease evolution, to be subjected to 
second-level investigations or a closer clinical follow-up. However, there is no unique consensus on 
thresholds and/or strategies that physicians ought to use in clinical practice whit the aim of avoiding 
liver biopsy 7,203.  
The major unmet needs, despite all the medical progress in the NAFLD field, is represented by the 
lack of non-invasive means allowing clinicians to identify subjects at risk of disease evolution. One 
branch of research has actively focused on soluble bio-markers, another one has moved towards 
genetic variables. 
In the last years, many authors have described increasing value levels of serum SCCA-IgM in 
patients suffering from chronic hepatitis (secondary to alcoholic and viral etiologies), liver cirrhosis, 
and HCC, but not in healthy controls 129,168,169, leading to the hypothesis that SCCA-IgM can 
represent a useful diagnostic marker for the presence of neoplasia and advanced hepatopathy.  
Martini et al. described how elevated plasma SCCA-IgM levels in patients with relative HCV liver 
disease are significantly associated with the presence of NASH at the histological level, but it is not 
clear if the presence of the immunocomplex is related to the presence of viral infection or 
steatohepatitis itself 204. There is a lack of data on the association between SCCA-IgM and fatty 
liver disease in the literature, so the first aim of this study is to investigate whether patients with 
NAFLD, in their different patterns of disease manifestation, present an autonomous production of 
SCCA-IgM/serpin B3 and whether their levels are predictive of liver illness evolution risk. 
Moreover, recently acquired robust evidence supports the role of genetic predisposition and 
heritability of NAFLD and HCC development; variants in the gene involved in the regulation of 
hepatic lipid metabolism, such as in PNPLA3, TM6SF2, MBOAT7, and GCKR, are strongly 
associated with hepatic fat content (HFC) and progression of liver diseases.  
Recently, Dongiovanni and co-workers 205 proposed the use of a weighted polygenic risk score 
(PRS) for hepatic fat accumulation based on SNC variants to stratify the risk of HCC development. 
As a secondary aim, we examined the impact of a polygenic risk score of hepatic fat content (PRS-
HFC), based on well-characterized risk genetic variants, on NAFLD-HCC in a cross-sectional 
cohort of at-risk individuals (NAFLD cross-sectional cohort). We tried to optimize it by adjusting 
for a protective variant in HSD17B13 (PRS-5). Finally, we aimed to identify the best diagnostic 
threshold. 






Patients with NAFLD (NAFL and NASH) diagnosed through clinical criteria (increased 
transaminases, exclusion of alcohol abuse, exclusion of other chronic liver diseases) and confirmed 
by histological examination were selected. 
84 patients with NAFLD were enlisted. 39 patients presented a histological diagnosis of liver 
steatosis and 45 of steatohepatitis. These patients were followed at the Liver Unit of the Hospitals 
of Udine (Medical Clinic), Trieste (Pathologic Liver Clinic), and Milan (Internal Medicine and 
Metabolic Diseases). 
The inclusion criteria were as follows: over 18 years of age, both sexes, confirmed clinical 
diagnosis of NASH or NAFL by a histological investigation. Patients who met the following 
exclusion criteria (condition inducing liver steatosis or increasing levels of the immunocomplex 
studied) were not enrolled in the study: a histological examination of a picture compatible with 
chronic liver disease evolved into cirrhosis; the presence of HCC; concomitance of HCV or HBV 
related infections; the presence of autoimmune liver disease, alpha1antitripsy deficiency, celiac 
sprue, hemochromatosis or Wilson's disease; daily alcohol consumption exceeding 30 g and 20 g 
for men and women respectively; exposure to hepatotoxic drugs or drugs inducing hepatic steatosis; 
a history of other types of cancer of epithelial origin; psoriasis, atopic dermatitis, allergic asthma 
and squamous skin carcinomas. The patients expressed their informed consent to grant access to 
their medical records and to participate in the study. 
The enrolled cohort for evaluation of SCCA-IgM was characterized through the evaluation of 
biochemical and anthropometric parameters of cardiometabolic risk. Weight, height, and waist 
circumference were measured. The BMI was calculated using the ratio between weight express in 
kilograms and the square of height express in meters. At fasting, blood samples were taken to 
determine: blood count with formula, phlogosis indices (C-reactive protein - CRP - and Erythrocyte 
Sedimentation Rate -ESR-), renal function (creatininemia and azotemia), electrolyte dosage 
(sodium, potassium, magnesium, calcium, phosphorus, chlorine), cytonecrosis and colostasis index 
(aspartate aminotranferases –AST-, alanine aminotransferases –ALT-, gamma-glutamyl 
transpeptidase –γGT- , alkaline phosphatase –ALP-, total and direct bilirubin), hepatic synthesis 
indices (international normalized ratio –INR-, albumin), pseudo-cholinesterase, glycaemia, 
insulinemia, c-peptide, glycated hemoglobin (HbA1c%), lipid profile (total cholesterol, LDL 
cholesterol, HDL cholesterol, triglycerides), Vitamin B12, folate, thyroid stimulating hormone 
(TSH), triiodiothyronine (fT3), thyroxine (fT4), cortisolemia, growth hormone (GH), insulin-like 
growth factor or somatomedin (IGF-1), homocysteinemia, lipotrotein(a) (Lp(a)), plasminogen 
activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), iron profile (sideremia, ferritin, 
transferrin, transferrin saturation). 
In non-diabetic patients, a glucose tolerance test was performed with 75 g of glucose and 
determination of blood glucose, insulin, and c-peptide levels at 0-60-90-120-180 minutes.  
The circulating SCCA-IgM complexes, dosed with the ELISA method, were also determined 
through a serum sampling in the morning, after an overnight fast, with the HepaIC kit (Xeptagen 
S.p.A., Venice). 
The HOMA-Index (insulin resistance index) was calculated: blood sugar (expressed in mg/100ml) 
multiplied by insulinemia (expressed in mUI / L) divided by 405 206,207.  
For each histological report, related to liver biopsy, the NAS score was defined, the SAF score and 
the patients were categorized into NAFL and NASH also based on the FLIP algorithm 92,208. 
The thickness of the subcutaneous (7.5 Mhz linear probe) and visceral (3.5 Mhz convex probe) fat 
was also measured. 
 
 
- PRS-HFC and PRS-5 
 
In the NAFLD/MAFLD case-control cross-sectional cohort, 1,699 patients with a diagnosis of 
NAFLD were enlisted (as defined in the guidelines7, thusly based on clinical, radiological, or 
histological characteristics, in which secondary causes of liver steatosis were ruled out ).  
These subjects, with European ancestry, were followed from 2008 until 2019, in several Italian 
(Milan, Udine, Trieste, Varese, Rome, Naples, and Palermo) and an English center (Newcastle upon 
Tyne), and were affected from different stages of liver disease: NAFL, NASH, cirrhosis, and HCC 
with or without severe degrees of fibrosis. Some of them underwent diagnostic biopsy during 
bariatric surgery. 
82 patients were enlisted in the Liver Unit of the Hospital of Udine (at Medical Clinic): 33 of which 
presented NAFLD with a low degree of fibrosis (F0-F2), 19 NAFLD with severe fibrosis (F3-F4) 
and lastly 30 with HCC related to NAFLD. 
Clinical (including sex, age, BMI, diagnosis of type 2 diabetes, histological features, NAS score) 
and biochemical data were collected and included in the analysis, when available. 
Moreover, 865 healthy subjects were enlisted as controls, matched for age and sex, without clinical 





Participants of both studies were genotyped for the rs738409 PNPLA3 I148M variant, rs58542926 
TM6SF2 E167K variant, rs641738 C>T MBOAT7 variant, rs1260326 GCKR P446L variant, and 
rs72613567 HSD17B13:TA variant.  DNA was extracted from peripheral blood mononuclear cells. 
Genotyping has been performed in nuclease assays duplicated by TaqMan 5’ at the Translational 
Medicine and Metabolic Liver Disease lab of the University of Milan.  
 
The genetic risk scores 
 
The genetic risk score (GRS), developed by Dongiovanni and colleagues 205, is based on the 
evaluation of cohorts of at-risk subjects and individuals from the general population enlisted in 
“Liver Biopsy Cohort” (LBC) 209, “Swedish Obese Subjects Study” (SOS) 210, and in particular in 
sub-groups of “Dallas Heart Study” (DHS) 211. For each patient enlisted the authors compiled 
information about genetic characteristic, referred to the major risk alleles involved in NAFLD 
predisposition (PNPLA3, TM6SF2, MBOAT7 and GCKR), and hepatic liver content obtained 
through biopsies (in LBC or SOS) or with proton magnetic resonance spectroscopy (in DHS). 
Mendelian randomization analysis demonstrated a specific impact of genetic variants on liver 
damage, that results proportional to their effect on hepatic fat accumulation.  The GRS represents 
the sum of the steatosis predisposing alleles in four genes (PNPLA3, TM6SF2, MBOAT7 and 
GCKR), weighted by their effect size on hepatic steatosis quantified by reference standard in the 
general population: [(0.266 x number of G alleles of PNPLA3) + (0.264 x number of T alleles of 
TM6SF2) + (0.063 x number of T alleles of MBOAT7) + (0.065 x number of T alleles of GCKR)]. 
In our study, we refer to it as PRS-HFC.  
Subsequently, a modified score of NAFLD was developed and adjusted for the rs72613567 
HSD17B13 variant 74, which we called PRS-5 (PRS-5: available in 2,532, 98.7%, coefficient: -
0.361). We reported the association of both instruments with phenotypes throughout the study since 
PRS-HFC is a proxy for genetic predisposition to accumulate liver fat, while PRS-5 considers all 











The data were analyzed using linear regression analysis for continuous variables and the Spearman 
Rank test for categorical ones. Besides, the Student "t" test, in case of parametric distribution, or 
Mann-Whitney test, in case of non-parametric distribution, was performed to compare the two 
groups of patients with hepatic steatosis and steatohepatitis. Finally, multiple regression analyzes 
and Chi-square tests were performed. P values <0.05 (two-tailed) were considered significant. 
 
- PRS-HFC and PRS-5 
 
For descriptive statistic, categorical variables are expressed as number and proportion, while 
continuous ones as mean and standard deviation (SD) or median and interquartile range (IQR), as 
appropriate. Observational associations were performed by fitting data to generalized linear models. 
Logistic regression models were employed to examine binary traits, and the association between 
PRS and liver disease was adjusted for age, sex, body mass index (BMI), type 2 diabetes (T2D), 
with or without further adjustment for the presence of severe fibrosis stage (F3-F4), the major risk 
factors for FLD and HCC, which were available for all individuals in the NAFLD cohort.  
To estimate the causal relationship between genetically determined predisposition to accumulate 
liver fat and HCC, Mendelian randomization analysis was used.  Mendelian randomization analysis 
is an epidemiological method that used measured variations in human genes with a known function 
to examine the presence of a causal effect of a modifiable exposure on disease or trait of interest in 
observational studies. It allows to obtain fair estimates of the outcomes of a putative causal variable 
when conducting a traditional randomized controlled trial, i.e. the ‘gold standard’ for empirically 
performing hypotheses in clinical research, is not practicable. This analysis is based on the concept 
that, since the distribution of alleles during gamete formation is random - independently of any 
other confounding factor, and interpersonal covariates are balanced among people with theoretically 
different polymorphisms, then genetic variation influencing a trait can be used to assess causality 
against another condition or characteristic of interest. For causal effects to be consistently 
evaluated, each instrumental variable (IV) used in this analysis must satisfy three key assumptions: 
(a) relevance assumption: the variable is associated with the exposure; (b) independence 
assumption: the variable shares no common cause with the outcome; (c) exclusion restriction 
assumption: the variable does not affect the outcome except through the risk factor 212–215. In 
Mendelian randomization analysis, the well-known HFC genetic risk variants expressed in PRS 
were employed as an instrument variable. The causal effect of hepatic fat on HCC was estimated by 
examining the PRS for association with liver steatosis and with HCC using a triangular approach: 
(a) the observational association between hepatic fat and HCC was examined in a traditional cross-
sectional study design. These observational associations can occur from both directions and can be 
biased due to confounding. (b) PRS are confirmed to be associated with fatty liver. (c) The 
association between PRS and HCC is tested. The genetic effect on HCC is assumed to be mediated 
by hepatic fat. Since genetic variants are inherited randomly at conception, the transmission of the 
effects may be assumed independent of other confounders. Moreover, genetic variation cannot be 
modified by phenotype, therefore ruling out reverse causation.  
The causal effect of genetic predisposition to fatty liver content on HCC was estimated by 
instrumental variable regression analysis in two-sample Mendelian randomization approached by a 
two-stage least squares regression procedure (using the ‘ivreg’ command in the AER package in R), 
which was adjusted for age, sex, BMI, and T2D. We assumed a lesser relevance or neutral impact 
of horizontal pleiotropic effects, that is an impact of the genetic variants on HCC risk independent 
of liver steatosis, that can invalidate the Mendelian randomization analysis. This was supported by 
the direct relationship between the risk conferred towards fatty liver content and HCC 
independently of the specific mechanism underlying the association with liver disease. The F 
statistics of the model was 107, thereby excluding weak instrument bias. Wu-Hausman p=0.09, 
suggesting that the causal estimate was consistent with the observational association – the test 
examines the difference between the instrumental variant (PRS) and the observational (fatty liver 
disease-FLD) association with the outcome (HCC). 
To further account for the possible pleiotropy of the genetic variants considered, was also included 
robust Mendelian randomization approaches via the Mendelian Randomization R package in our 
sensitivity analyses 215. The inverse-variance weighted (IVW) method is the equivalent to the 
standard instrumental method using individual-level data (the two-stage least squares method 
reported above) but can be performed on summarized data. The robust option uses robust regression 
rather than standard regression in the analyses, and the penalized option down-weights the 
contribution to the analyses of genetic variants with outlying (heterogeneous) causal estimates. The 
median- and mode-based methods calculate respectively a median or mode of the variant-specific 
causal estimates from the ratio method for each genetic variant individually. The MR-Egger method 
can assess whether genetic variants have pleiotropic effects on the outcome that differ on average 
from zero (directional pleiotropy), as well as to provide a consistent estimate of the causal effect, 
under a weaker assumption-the InSIDE (Instrument Strength Independent of Direct Effect) 
assumption. The intercept from the MR-Egger analysis can be interpreted as the average pleiotropic 
effect of a genetic variant included in the analysis. The maximum likelihood involves maximizing a 
likelihood that has one parameter for each genetic variant, plus a causal effect parameter. The 
heterogeneity-penalized method uses the same consistency criterion as the mode-based estimation 
method but evaluates the modal estimate by assessing weights for all subsets of genetic variants. 
Mediation analysis was conducted to estimate the fraction of the effect of hepatic fat accumulation 
– FLD on HCC predisposition, which is mediated through the development of severe fibrosis. 
Analyses were conducted by the “mediation” package in R (http://CRAN.R-project.org/ 
package=mediation). We used model-based causal mediation analysis (“mediate” function), 
calculating quasi-Bayesian confidence estimated with 1,000 simulations. In a Mendelian 
randomization framework, a positive PRS score, indicating increased genetic predisposition, was 
treated as active treatment/exposure. The analysis was adjusted for age, sex, BMI, and T2D.  
Furthermore, we determined the thresholds in the PRS able to identify individuals at higher genetic 
risk of HCC. Diagnostic accuracy of PRS was evaluated by receiver operating characteristic (ROC) 
curves, and the best cut-off identified as the value that maximizes the difference between true 
positives and false positives (sensitivity+specificity-1). 
Statistical analysis was carried out using the JMP Pro 14.0 Statistical Analysis Software (SAS 
Institute, Cary, NC), and R statistical analysis software version 3.5.2 (http://www.R-project.org/). P 






84 patients were enrolled, 39 of which with histological diagnosis of NAFL (46,4%) and 45 with a 
liver biopsy of NASH (53,6%), whose anthropometric characteristics, the main bio-humoral 
indices, and the levels of SCCA-IgM are shown in table 5. 
The analysis of the collected data showed that patients with NASH were significantly younger (50.7 
± 2.8 years vs NAFL 57.4 ± 1.6 years; p = 0.03) and characterized by a higher body weight (97.2 ± 
4.7 kg vs NAFL 85.9 ± 2.9 kg; p = 0.02) compared to those with a histological picture of steatosis 
alone. 
A statistically significant difference (p = 0.001) was even observed in terms of BMI. Patients with 
NASH have higher BMIs (34.9 ± 1.7 kg/m2) than the group of patients with NAFL (29.1 ± 0.6 
kg/m2). While no significant differences were found comparing values of the waist circumference 
(101.8 ± 3.2 cm and 102.2 ± 2.1 cm respectively for NASH and NAFL), thickness of the 
subcutaneous fat (24 ± 3 mm and 23 ± 1 mm respectively for NASH and NAFL), and thickness of 
visceral fat (64 ± 5 mm and 69 ± 3 mm for NASH and NAFL respectively) measured by ultrasound. 
In the two groups there were no statistically significant differences in terms of glycemia (100 ± 3.7 
mg/dL and 103.9 ± 4 mg/dL respectively for NASH and NAFL), glycated hemoglobin (6.5 ± 0.2 % 
and 6.2 ± 0.1% respectively for NASH and NAFL), insulin (49.5 ± 29.7 mUI/L and 23.9 ± 6.2 
mUI/L respectively for NASH and NAFL) and HOMA-index (5.2 ± 1.1 and 4.1 ± 0.4 respectively 
for NASH and NAFL). However, we have to underling that patients with NASH presented higher 
insulin values and higher HOMA-index compared with whom present only steatosis, levels this that 
are compatible with an IR condition. 
The evaluation of the lipid profile, while not showing statistically significant differences, between 
the two groups, in terms of HDL cholesterol (55 ± 2 mg/dL and 56 ± 3 rmg/dL respectively for 
NASH and NAFL) and triglycerides, shows that the latter are higher in patients with NASH than in 
patients with NAFL (158 ± 18 mg/dL and 143 ± 10 mg/dL or NASH and NAFL respectively). The 
dosage of total cholesterol (222 ± 8 mg/dL and 200 ± 5 mg/dL respectively for NASH and NAFL; p 
= 0.02) and LDL cholesterol (138 ± 7 mg/dL and 116 ± 5 mg/dL respectively for NASH and 
NAFL; p = 0.01) instead result significantly higher in subjects witch NASH. 
Considering the cholostasisi indices, the two groups of patients are homogeneous (γGT 65 ± 9 U/L 
and 93 ± 31 U/L respectively for NASH and NAFL; total bilirubin 0.7 ± 0.1 mg/dL and 0.7 ± 
0.1mg/dL  respectively for NASH and NAFL). 
The AST dosage was not significantly dissimilar in the two groups (28 ± 2 U/L and 30 ± 2 U/L for 
NASH and NAFL, respectively). The ALT value is significantly lower in patients with 
steatohepatitis than in patients with steatosis alone (31 ± 4 UI/L and 39 ± 2 U/L respectively for 
NASH and NAFL; p = 0.05), furthermore the AST/ALT ratio results statistically significantly lower 
in patients with NASH compared to NAFL patients (1.1 ± 0.1 and 1.4 ± 0.1 for NASH and NAFL, 
respectively; p = 0.01). 
No statistically significant differences were observed between the two groups in terms of C reactive 
protein (CRP) level (3.7 ± 1.2 mg/L and 13.4 ± 0.8 mg/L respectively for NASH and NAFL), PAI 
(14 ± 2 U/mL and 19.8 ± 4.8 U/mL for NASH and NAFL respectively), tPA (7.5 ± 0.8 ng/mL and 
10.3 ± 1 ng/mL for NASH and NAFL respectively), Lp (a) (21 ± 6 mg/dL and 25 ± 6 mg/dL for 
NASH and NAFL respectively) and ferritin (179 ± 41 mcg/L and 213 ± 32 mcg/L for NASH and 
NAFL respectively). While patients with NASH were shown to have statistically significant higher 
TSH levels (2.2 ± 0.2 mU/L and 1.4 ± 0.1 mU/L for NASH and NAFL, respectively; p = 0.001). 
Furthermore, in patients with NASH higher IGF-1 values were detected than in patients with 
NAFL, at the limits of statistical sensitivity (122 ± 15 ng/mL and 97 ± 7 ng/mL, respectively for 
NASH and NAFL; p = 0.09), while no differences are detectable when plasma cortisol levels were 
compared (323 ± 44 mcg/L and 361 ± 22 mcg/L for NASH and NAFL, respectively). 
Finally, we observed the presence of significantly higher levels of  SCAA-IgM in patient with 
NASH compared with levels detected in those presenting only NAFL (31.7 ± 7.2 IU / mL vs 9.2 ± 
1.8 IU/mL respectively) (figure 6). 
Statistical regression analysis found a statistical correlation between SCCA-IgM levels, age (p 
<0.05; r = 0.269), BMI (p = 0.01; r = 0.3), homocysteinemia (p = 0.02; r = 0.33), and SAF-F score  
(p < 0.05; r = 0.29). No correlation was found with the degree of steatosis, inflammation and 
ballooning detected on liver biopsy, with the average-intimal thickness of visceral and subcutaneous 
fat, nor with the alteration of the indices of cytonecrosis (table 6). 
By dividing the levels of SCCA-IgM into quartiles, four different groups were identified on the 
basis of plasma concentrations: the first quartile between 0.06 IU/mL and 3.01 IU/mL with mean 
SCCA-IgM of 1.98 ± 0.67 IU/mL; the second quartile included concentrations ranging from 3.18 to 
5.6 IU/mL with a mean of 4.11 ± 0.67 IU/mL; the third between 6.8 and 10.23 IU/mL, with an 
average concentration of 7.95 ± 1.33 UI/mL; the fourth with values between 12.2 and 201.92 
IU/mL with an average concentration of 35.31 ± 46.39 IU/mL. Thusly, we demonstrated that 
patients with higher SerpinB3 concentrations presented histological pictures characterized by more 
marked fibrosis, significant in statistical terms (p < 0.05) (figure 7). 
Finally, we dosed free-Serpin3/SCCA, testing the hypothesis that it could increase the sensibility of 
the biomarker and aiming to evaluate whether the ratio between the free form and IgM-linked one 
could better identify NASH and eventually replace biopsy. Although the dosage of Free-SCCA was 
higher in patients with NASH compared to those with NAFL (1.7±0.4 ng/mL vs 1.4±0.1ng/mL, 
respectively), it still did not reach statistical significance. Free-SCCA/SCCA-IgM ratio turned out 
to be statistically significant in patients with NAFL (22.3±3.7 ng/mL in subjects with NASH vs 




- PRS-HFC and PRS-5 
 
1699 patients with different stages of NAFLD and 865 healthy subjects, all with European ancestry, 
were enlisted in the cross-sectional NAFLD cohort study. Demographic and PRS characteristic are 
shown in table 7. 
We observed that patients with severe fibrosis (F3 -F4) and HCC were older ( 58±14 years and 
69±9 years NAFLD F3-F4 and HCC respectively compared with 42±16 years and 44±6 years in 
NAFLD F0-F2 and control group respectively; p<0.0001) and had higher prevalence of type II 
diabetes in NAFDL with F3-F4 degree and HCC respectively, compared with patients prevalence 
observed in subjects with low fibrosis degree (F0-F2) and with controls (56.9% and 64.2% NAFLD 
F3-F4 and HCC respectively compared with 20.2% and 0.9% in NAFLD F0-F2 and control group 
respectively; p<0.0001).  
HCC patients were more frequently male: we observed that male prevalence in the evaluated groups 
is respectively 78.8% in HCC, 57.6% in NAFLD with F3-F4, 57.6 in NAFLD with F0-F2 and 
52.6% in healthy individuals (p<0.0001). 
PRS-HCF increased progressively according to the severity of the liver disease (0.266, 0.392, 
0.457, and 0.459 respectively in controls, NAFLD F0-F2, NAFLD F3-F4 and HCC; p<0.0001). 
Whereas PRS-5 result higher in patients with severe fibrosis than in subjects with HCC (patients 
with NAFLD F3-f4 present PSR-5 median equal to 0.421 compared with 0.233 observed in 
controls, 0.329 in NAFLD F0-F2 and 0.33 in NAFLD-HCC; p<0.0001). 
Through Mendelian randomization we have examined the relationship between the impact of 
genetic risk variants on liver steatosis and that on severe liver fibrosis and HCC (figure 9). The 
increase in the risk of HCC conferred by risk genetic polymorphisms was proportional to the 
increase in the risk of NAFLD (p=0.02). Furthermore, the analysis revealed the presence of a direct 
relationship between the risk conferred to NAFLD and severe fibrosis (p=0.0001), and between 
severe fibrosis and HCC (p=0.002).   
Using PRS as instrument in Mendelian analysis, we demonstrate that HFC was causally associated 
with HCC (beta +0.30±0.06, OR 1.35, 1.18-1.58, p=1*10-5 for PRS-HFC, and beta +0.29±0.07, OR 
1.27, 1.10-1.45, p=1*10-5 for PRS-5) independently of age, sex, BMI, and presence of T2D. With 
the aim of estimating the weight of the effect of fat accumulation on HCC development 
predisposition, mediated by the progression of the fibrosis, we used mediation analysis. The 
association coefficient was attenuated by 37-41%, but remained statistically significant, after further 
correction for severe liver fibrosis (p<0.05).  
We estimated causality using a wide range of modern Mendelian randomization approaches, which 
considered the possible pleiotropy of the effects of the genetic instruments (a direct impact on HCC 
not mediated by HFC). Other sensitivity analyses were generally consistent with a causal effect of 
FLD on HCC (table 8). 
By assimilating the score to a continuous variable, linear regression analysis highlighted the 
existence of a statistically significant association between PRSs and the entire spectrum of NAFLD. 
The impact of both PRSs on the full spectrum of liver disease in the NAFLD cohort is reported in 
figure 10. PRS result associated with an about 12-fold increased OR of severe fibrosis (p<10-27 for 
both) and an about 9-fold increased OR of HCC (OR=9.2, 5.2-16.3, p=2.7*10-14 and OR=9.1, 5.2-
16.0, p=1.6*10-14, respectively for PRS-HCF and PRS-5). The association was independent of age, 
sex, BMI, and T2D (p<0.01 for both PRSs), but not of severe fibrosis (p>0.1). In the NAFLD 
cohort, there was no significant association between PRS and BMI, T2D or HOMA-IR in 
determining HCC risk (p>0.1). These results are consistent with a causative effect of genetic 
predisposition to hepatic fat accumulation on carcinogenesis, partially mediated by severe fibrosis, 
but independent on T2D presence. 
The AUROC of PRS-HFC for HCC diagnosis was 0.64 and for PRS-5 was 0.65 (table 9 and figure 
11).  
The best single cut-off value for PRS-HCF was ≥0.532, with 43% sensitivity and 80% specificity. 
As regards to PRS-5, the corresponding cut-off (43% sensitivity and 79% specificity) was ≥0.495 
(table 9 and figure 11). Therefore, we defined PRS-HFC ≥0.532 and PRS-5 ≥0.495 as “positive” 
tests. A positive PRS-HFC was associated with a 3-fold higher risk of HCC, and a positive PSR-5 
with a 2.9-fold risk (p<10-12 for both). In the NAFLD cohort, prevalence of positive tests was 22.2% 
for PRS-HFC and 22.9% for PRS-5. 
Both PRS were able to predict the risk of HCC development more robustly than single variants, 
with PRS-5 conferring a slight improvement over PRS-HFC (table 10).  
The sensitive analysis demonstrated that positive PRSs is associated with HCC increased risk even 
in individuals without severe fibroses (OR>2.0, 1.1-3.8, p=3.3*10-2 for PRS-HFC and OR=2.3, 1.2-
4.5, p=1.2*10-2 for PRS-5; figure 12). Furthermore, positive tests improved HCC detection in 
subjects over 40 years independently of severe fibrosis (OR=1.5, 1.1-2.2, p=1.0*10-2 for PRS-HFC 
and OR=1.5, 1.1-2.1, p=2.4*10-2 for PRS-5). Finally, PRS-5 can predict HCC risk even in non-
obese subjects (OR=3.5, p=7.2*10-9) 
The results of analysis for the 82 patients enlisted in Udine were consistent with what was observed 
in the completely NAFLD cohort. In particular, the patients with HCC were significantly older than 
those with NAFLD and controls (69±9 years, 59±9 years, 57±9 years, and 45±6 years respectively 
for HCC, NAFDL F3-F4, NAFLD F0-F2 and controls; p=5,00E-94). No significant differences 
were observed in regard to gender. Patient with NAFLD (F3-F4) presented significantly higher 
BMIs (20.3±6.7 kg, 31±4.1 kg, 28.2±4 kg, and 24.1±1.9 years respectively for HCC, NAFDL F3-
F4, NAFLD F0-F2 and controls; p=2,50E-64). Individuals with HCC were more frequently affected 
from type II diabetes (63.3%, 31.6%, 15.1% respectively in HCC, NAFLD F3-F4 and NAFLD F0-
F2; p= 2,40E-36). Subjects with HCC and NAFLD-F0-F2 presented PRS-HCF median higher 
levels (0.266, 0.459, 0.331, and 0.459 respectively in controls, NAFLD F0-F2, NAFLD F3-F4 and 
HCC; p= 4,03E-09), NAFDL F0-F2 group were characterize by median higher levels of PRS-5 
(0.223, 0.426, 0.224, and 0.396 respectively in controls, NAFLD F0-F2, NAFLD F3-F4 and HCC; 
p=4,79E-09). Baseline characteristic are reported in table 11.  
Even in the Udine subgroup, both PRSs results were able to predict the full spectrum of liver 
disease at univariate analysis. After adjusting for clinical variables, only PRS-5 can predict NAFLD 
risk, PRSs do not result independently from age, sex, BMI, presence of type II diabetes and 
advanced fibrosis (table 12). Logistic regression analysis shows that PRSs predict HCC risk 
development better than single genetic variable (p=2.20 E-05 for PSR-HFC and p=4.50E-04 for 
PRS-5). Among the latter, only PNPLA3 I148M, demonstrates significant power (p=1,80E-03) 
(table 13). However, significance is lost when we adjust the analysis on the basis of the main 
clinical variables. Finally, the performance test shows for both PRSs a AUROC equal to 07. The 
prevalence of patients with PRS-HCF equal or higher than 0.532 were observed in 14.1% of the 
individuals enrolled, and a similar prevalence resulted for cut-off equal or higher than 0.495 for 
PRS-5. Both the scores were characterized by 40% of sensitivity and 86% of specificity (table 14). 
We did not find association between PRSs and SCCA-IgM levels in a subgroup of patients, for 
whom both the non-invasive tools were analyzed. Evaluating the single variants, only GCKR 





Our first study aim is to evaluate whether, in a selected group of patients with histological 
characterized purely metabolic liver disease, the dosage of SCCA-IgM/SerpinB3 is significantly 
higher in patients with steatohepatitis than in those suffering from steatosis alone. 
In 2015, Martini et al. demonstrated the existence of an association between the levels of SCCA-
IgM and the presence of steatohepatitis at histological examination in a group of patients with 
chronic HVC infection. The SCCA-IgM immunocomplex was more often detected in subjects with 
related HCV infection than in patients with negative serology (34.9% vs 4.3% respectively; P 
<0.0001) 170. Moreover, about one third of the patients with chronic HCV-related liver disease had 
elevated levels of SCCA-IgM. These concentrations correlated with the presence of a histological 
picture of NASH and with the genotype 3 of HCV, which is usually associated with more marked 
insulin resistance and hepatic steatosis 216 . 
The dosage of the SCCA-IgM immunocomplex in our population turned out to be inferior from 
limits so far proposed in the literature by the studies of Turato and colleagues, equal to 160 U / mL 
217, or used by Martini and coworkers, equal to 200 U / mL 170, or by Cagnig et al. equal to 120 
U/mL 218 . In only one case we found a value equal to 201.92 U / mL, relating to a patient suffering 
from severe obesity. Overall, although the distribution from the concentrations is characterized by a 
wide dispersion and variability, we found that, in patients diagnosed with steatohepatitis, the 
dosages of the immunocomplex were almost thrice as high as those of patients with simple hepatic 
steatosis, thus reaching statistical significance.  
Interesting individuals with higher degrees of SAF-F score shown at histological liver evaluation 
presented a significantly higher concentration of SCCA-IgM. This is consistent with what has been 
reported so far in the literature: the existence of an association between conditions characterized by 
fibrosing evolution, advanced or worsening liver disease, and an increase in the biomarker 217,218. 
Unlike what has been observed in the literature, we can explain the lower levels or SCCA-IgM 
detected by considering the characteristics of our patients: they present an initial picture of NASH, 
without high degrees of inflammation, ballooning or, in particular, fibrosis, resulting far from 
cirrhosis and obviously being free from heteroplastic pathology. This last condition in particular 
showed higher levels of the immunocomplex in the previously mentioned studies. 
Martini et al. also showed that patients not affected by HCV-related chronic infection had lower 
levels of circulating immunocomplex. From a purely speculative point of view, we can therefore 
hypothesize that the concomitant presence of the hepatotropic virus has favored and amplified, 
through the continuous cytotoxic damage, the induction of SCCA-IgM/SerpinB3 production. 
Recently, Bettini et al. evaluated SCCA-IgM as a non-invasive biomarker in 56 patients with 
metabolic complicated obesity before and up to 12 months after laparoscopic sleeve gastrectomy 
219. Presence of liver steatosis was evaluated only through ultrasound scans (16 without liver 
steatosis and 40 with it). It should be noted that the average starting BMI in subjects was found to 
be 44 kg/m2 and 46 kg/m2 for those without and with ultrasound observed liver steatosis 
respectively. Only one patient had a histological diagnosis of NASH, however the author did not 
share data about the presence of fibrosis or inflammation, however the reported immunocomplex 
concentration fell within the normal range. Even in this cohort, only 3 subjects presented 
immunocomplex levels above the “normal cut-off”. The author did not observe a significant 
difference in SCCA-IgM levels between patients with and without liver steatosis. After gastrectomy 
a reduction in the levels of SCCA-IgM in both groups was observed, however they did not reach 
statistical significance. No association between the decrease of immunocomplex concentrations and 
the reduction in inflammation maskers (as IL-6, leptin and hsCRP) was found 219. This study has 
several limitations, first of all subject with severe obesity were categorized as either having steatosis 
or not only on the basis of an abdominal ultrasound study, which is extremely operator dependent 
and hardly provides information on any regressions/improvement of the pathology. No histological 
information and stratification according to a pathological scoring system was available. Even the 
use of transaminase as a tool to identify NAFLD disease presents several limitations, as previously 
discussed. Moreover, the author did not exclude patients with concomitant autoimmunity disease, 
which explains the increased levels of SCCA-IgM detected in 3 subjects. Considering the 
characteristics of SCCA-IgM, we can expect higher levels, regardless of the cut-offs proposed so 
far, in individuals with liver fibrosis and inflammation. Obviously, according to current literature, 
the higher the titers the more pronounced these phenomena are (such as during viral infections, 
alcohol abuse, overt cirrhosis, and HCC).  
Our initial proposal was furthermore to test the possible uses of this immunocomplex in providing 
the definition of NAFLD disease evolution risk, following patient according to anthropometric, 
ARFI, and biohumoral data. Unfortunately, the bankruptcy of the manufacturer of the kit and the 
absence of similar products on the world market prevented the prospective development of the 
research.   
However, further studies evaluating the kinetics of production and disposal of SCCA-IgM and 
determining whether different cut-offs can be defined in the context of the different etiopathologies 
and degrees of evolution of chronic liver disease will be necessary. 
To date, no studies have been published in the literature relating to the dosage of SCCA-
IgM/SerpnB3 in a population with the characteristics of the one we selected, so the evaluations we 
can make here are purely speculative. 
Just as we will be able to explain the reduced levels of free-SCCA found in patients with simple 
liver statosis, referring to the fact that in NAFL there are reduced levels of inflammation compared 
to those with NASH. Consequently, the free-SCCA/SCCA-IgM ratio is higher in patients with 
steatosis alone.  
Regression analysis showed the existence of a correlation between SCAA-IgM and age, BMI, 
homocysteinemia and SAF-F score. 
The association with age and BMI could be intuitive. In the literature, several studies have observed 
that patients with non-alcoholic fatty liver disease are characterized by having an average age of 
about 40-50 years and a high BMI 27. In particular, the prevalence of NAFLD increases with 
increasing age, and aging itself rapresent, as already described above, an independent risk factor for 
the development of fibrosis and cirrhosis 88.  
Although liver disease progression may represent the result of a complex sum and interplay of 
metabolic events, risk factor exposure, and long-lasting metabolic disease 171, some longitudinal 
studies do not seem to consistently indicate that age itself has an impact on the rate of progression 
of hepatic fibrosis 173. 
In our study, patients diagnosed with steatohepatitis were on average younger than those with 
hepatic steatosis alone. Although our sample was affected by a bias related to the presence of 
younger patients, as they were candidates for bariatric surgery; SCCA-IgM levels correlate with 
age, suggesting that, on average, a higher age is associated with a more prolonged exposure to 
pathogenic noxa and a pabulum of pro-inflammatory cytokines favoring the production and release 
of the immunocomplex by the hepatocytes. 
Over the years, a growing and consolidated literature has shown how obesity, as a constituent 
element of the metabolic syndrome, is a risk factor for the development of NAFLD. In some 
populations of patients undergoing bariatric surgery, about 90% had NAFLD, and about 5% were 
affected by unrecognized cirrhosis 220. Pang et al. described how every one-point increase in BMI 
increases the risk of developing NAFLD by 0.25 221. Although the population studies are limited 
and difficult to perform, since hepatic needle biopsy is an invasive diagnostic procedure not free 
from the risk of complications, some authors have described, in selected groups of patients, how the 
degree of hepatic steatosis appears to correlate with BMI 222. In particular, this could be linked to 
the increased thickness of visceral fat observed in patients with (i) progressively increasing stages 
of obesity, (ii) increasing de novo lipogenesis – an altered secretion and sensitivity of peripheral 
tissues to adipokines (adiponectin, resistin, leptin) -, and (iii) a low, but chronic, degree of 
inflammation, with the presence of a circulation of pro-inflammatory cytokines (IL-6, IL-1β, TNF-
β, TNF-α) which, in their complex, favor the development and progression of liver disease on a 
metabolic basis 223. Unfortunately we do not have information about pro-inflammatory cytokines in 
our cohort. The levels of SCCA-IgM in our study correlate with the BMI, which is consistent with 
our hypothesis that subjects with higher BMI have a greater degree of obesity and are characterized 
by a greater thickness of visceral fat, which in turn contributes to oxidative stress and the 
production of pro-inflammatory cytokines favors the development of hepatocyte damage and, 
therefore, the release of SerpinB3. In patients with higher BMI there is a higher prevalence of 
NASH and therefore greater induction and release of SCCA-IgM. Unfortunately, compared to what 
we expected, we did not identify statistically significant differences in terms of subcutaneous fat 
thickness, measured by ultrasound, between patients with steatosis and steatohepatitis. 
Although we were not able to demonstrate the existence of a correlation between SCCA-IgM 
concentrations and the degree of inflammation and ballooning described on the biopsy, a correlation 
was nevertheless observed with the degree of fibrosis expressed by SAF-F score. This is consistent 
with the detection of a statistically significant association between fibrosis and the highest 
concentrations of SCCA-IgM, thus perhaps suggesting that fibrosis may have a greater weight in 
the induction of this molecule. Turato and coworkers described the presence of high concentrations 
of a variant of SerpinB3, called SCCA-1 (SCCA-PD), resulting from a single mutation at the level 
of Gly351Ala in subjects affected by liver cirrhosis and hepatocellular carcinoma. In this case the 
serpin levels were higher in patients with advanced liver disease than in healthy controls or in 
patients with chronic liver disease 217. This finding can therefore lead to the hypothesis that elevated 
stages of hepatic fibrosis are one of the elements that contribute to the production, disposal, and 
formation of the immunocomplex. Our NASH patients had mild degrees of inflammation and 
ballooning (with NAS score equal to or just above the diagnostic limit for NASH) as well as mild 
degrees of fibrosis, so could be categorized as early NASH 7. These conditions could explain why 
the SCCA-IgM levels do not show the marked increased we expected from the perusal of other 
antecedent studies observed in the literature.  
The correlation detected with homocysteinemia is less immediate and could appear to be purely 
coincidental. There are not many works in the literature relating to the association between 
homocysteinemia and NAFLD. Most of the methionine introduced through the diet is metabolized 
in the liver, so we can say that this organ plays a central role in the synthesis and metabolism of 
homocysteine. In the literature, it has been reported that patients affected by alcohol-based hepatitis 
or liver cirrhosis have reduced homocysteine levels compared to the general population 224. Some 
authors have highlighted how hyperhomocysteinemia seems to be associated with NAFLD, unlike 
what is observed in patients with viral hepatitis or in the general population 224,225. The data relating 
to the levels of homocysteinemia during NASH are not univocal: cases have been reported in which 
an increase in levels was found 224 and others in which the levels are lower than in controls with 
steatosis alone 226. Homocysteine would favor the development of IR, inducing the synthesis of 
glycogen and insulin through its metabolite, homocysteine thiolactone. High levels of the latter 
hormone would regulate the levels of homocysteine itself, thus favoring the establishment of a 
vicious circle between IR and hyperhomocysteinemia 227–229. It has also been described how 
conditions of hyperhomocysteinemia are responsible for alterations in the composition of plasma 
lipids and favor their tissue accumulation, thus inducing the development of hepatic steatosis 230,231. 
Several authors have also highlighted, mainly on mouse models, how homocysteinemia can induce 
stress at the ER level, thus causing an altered regulation of the sterol pathway 232–235. Finally, it is 
now a consolidated fact that hyperhomocysteine plays an active role in endothelial damage by 
causing a reduction in nitric oxide levels and favoring thrombosis of the microcirculation 236–238. If 
these phenomena also affect the hepatic sinusoids, this condition could account for of a further 
pathogenetic mechanism that would explain its role in the context of NAFLD. Polyzos et al. 
demonstrated that homocysteinemia levels in NASH patients are lower than those found in NAFL 
patients, identifying the existence of a correlation between homocysteine levels and degree of 
steatosis, inflammation and portal fibrosis, and going so far as suggesting the use of this hormone as 
an independent predictor of NASH 239. In fact, it has been hypothesized that a reduction in 
homocysteine levels may be secondary to an alteration in the equilibrium of homocysteine 
metabolism, both through the remethylation pathway and the transulfuration pathway. Through this 
first, and then using the available methyl groups, homocysteine would be consumed for the 
constitution and release of VLDL from the liver into the circulation. The increasing degree of 
oxidative stress involved in the most advanced stages of the disease would require a progressive and 
continuous consumption of glutathione reductase, which is then regenerated through the 
transulfuration pathway, always starting from homocysteine. Furthermore, a reduced availability of 
methyl groups would result in a reduced synthesis of phosphatidylcholine, which plays a key role in 
the assembly and release of VLDL from the liver, thus favoring the further accumulation of lipids at 
the hepatocyte level and thus helping to support the steatosis itself 239. The data deriving from our 
work are consistent and agree with what was found in previous research, in fact in our patients with 
NASH the homocysteine levels are 12.8 ± 0.6 µmol/L while in those with NAFL of 13.4 ± 0.8 
µmol/L. It can therefore be hypothesized that high homocysteine levels favor the development of 
hepatic steatosis through various mechanisms ranging from the maintenance of IR to the alterations 
of the lipid profile, from the accumulation of fatty vacuoles in hepatocytes to the induction of 
thrombosis of the microcirculation, from the reduction of release of nitric oxide from endothelial 
cells to the production of inflammatory cytokines by monocyte/macrophage cells. Over time, the 
progression of the disease and the perpetuation of oxidative stress would induce a drop-in 
homocysteine levels which could participate in the development of steatohepatitis, through a 
reduction in the levels of antioxidants and favoring the accumulation of hepatocyte lipids. Perhaps 
precisely because of this reduction in concentrations observed in patients with NASH, the studies 
that attempted to verify the effectiveness of a treatment by administering B vitamins and folic acid 
did not yield positive results 240,241. In light of these findings, the correlation between SCCA-IgM 
and homocysteine levels, which emerged in our population, may be consistent with an 
etiopathological hypothesis and with the data collected in the literature. Both of these phenomena 
are associated or are the result of a marked oxidative stress affecting the hepatocytes. Further 
studies and investigations must be carried out to verify the validity of this hypothesis and these 
findings. However, it should be emphasized that, with regard to the population under examination, 
we have no information regarding the genetic characteristics of the state of methylene-
tetraidofolate-reductase (MTHRF) or any vitamin B6 deficiency. While, all patients had 
concentrations of vitamin B12 or folic acid within the normal limits. 
From the comparison between the two groups of patients, it emerged that subjects with a 
histological diagnosis of NASH had a statistically lower age than patients with hepatic steatosis, as 
well as a higher weight and BMI. 
The average age of the two groups is comparable to that reported in the literature in which the 
greater prevalence of NAFLD is observed. The fact that the NASH patients in our study were on 
average younger than those with NAFL can be explained by the fact that of the 45 patients enrolled 
with a histological diagnosis of hepatic steatosis, 10 (23%) were candidates for bariatric surgery. 
This same element can also account for the data collected regarding the fact that patients with 
NASH had on average a higher weight and a higher BMI. Weight and BMI are known risk factors 
for the development of metabolic syndrome, fatty liver disease, its evolution into steatohepatitis and 
the progression of fibrosing damage, as already extensively discussed above. BMI consistent with 
literature data can be considered a predictor of the severity of NAFLD 242.  
The glycemic profile and glycated hemoglobin are comparable in the two groups, not detecting 
statistically significant differences. The liver itself is an organ involved in the development of 
diabetes mellitus: it is in fact closely linked with IR, in turn suffering complications but also feeding 
and lying to this condition. Patients with type II diabetes mellitus have an approximately 40% risk 
of developing NASH, and have greater degrees of hepatocyte damage than those who do not have 
this disease 243–245. The same NAFLD fibrosis score, devised by Bazik and co-workers, on the basis 
of these observations, is aimed at identifying patients at greater risk of presenting NASH and 
advanced fibrosis in diabetic patients with radiological evidence of hepatic steatosis 246. In the 
population examined in this study, glycated hemoglobin levels were significantly higher in patients 
with steatohepatitis than in those who were not affected. Barros et al. also found elevated levels of 
glycated hemoglobin in their severely obese and NAFLD patients, but did not check whether there 
were any differences between patients with steatosis and steatohepatitis 247. In our "population" in 
both the two groups average values were found at the limits of the diagnosis of impaired fasting 
glycaemia. Glycated hemoglobin was on average within normal limits, an expression of adequate 
glycometabolic compensation in both groups of patients, even in those with histological pictures 
compatible with greater hepatocyte damage and fibrosis. There was no difference in the prevalence 
of type II diabetes mellitus in the two groups under review. In part this can be explained by the 
limited sample size, in part by an adequate management of diabetes mellitus expressed in terms of 
good glycometabolic control through adequate pharmacological therapy or guaranteed by a marked 
inulinemia. A discrepancy can be observed between the insulin-concentration and HOMA-index 
means in the two groups of patients can be observed, albeit one that does not reach statistical 
significance. In both groups there is a marked increase in insulin levels, more marked in patients 
with NASH, in which there is also a more marked dispersion of the values. This last element in 
particular could account for the failure to achieve significance in statistical terms. The finding of 
hyperisulinemia, in addition to being consistent with the literature and with the etiopathogenetic 
mechanisms underlying NAFLD, is a direct consequence of the degree of obesity, expression of 
excess weight, and high BMI. Subjects in both groups have a diagnostic HOMA-I by IR, with 
values in both cases higher than the diagnostic cut-off (equal to 2.5), although it is higher in patients 
with steatohepatitis. These data confirm the high level of IR that characterizes these patients and is 
consistent with the data collected in the literature. The role of IR in the etiopathogenesis of NAFLD 
has also been extensively investigated. Park et al. in the biopsies of a group of pediatric patients, 
recently found that those who were characterized by a more pronounced IR presented more severe 
pictures of lobular inflammation and fibrosis, suggesting its possible use to identify NASH patients 
in lieu of a liver biopsy 248. 
The dosage of total cholesterol and LDL cholesterol was significantly higher in patients with NASH 
than in those with steatosis alone. This is also consistent with the current literature, in fact obese 
patients with NAFLD have higher concentrations of LDL cholesterol, compared to those who are 
not suffering from fatty liver disease 247. Siddiqui and colleagues demonstrated in their case control 
study that NAFLD patients had higher levels of free fatty acids and LDL cholesterol than patients 
who did not have fatty liver disease, regardless of whether or not obesity was present 249. NAFLD is 
characterized by having alterations in the lipid profile with a prevalence of pro-atherogenic 
lipoproteins, an increase in LDL, triglycerides and a reduction in HDL cholesterol levels 250,251. 
However, it has been suggested that this different lipid profile is a direct consequence of the liver 
lipid content and IR, and that it does not appear to be linked or worsened by the degree of obesity or 
the severity of the disease in terms of progression to steatohepatitis 252. In our study, triglyceride 
levels were higher in patients with NASH, although they did not reach statistical significance.  
In the subjects evaluated in our study, on average, both in patients with fatty liver and in those with 
a history of steatohepatitis, the levels of the indices of cytonecrosis and colostasis were within 
normal limits. Even if we observed that patient with NASH were characterize by statistical 
significant lower levels of ALT compared to subjects with simple steatosis. These results are 
consistent with the finding that in 50-80% of NAFLD patients no alteration of hepatic cytolysis 
indices are observed 253. In the literature, it has been reported that patients with NAFLD tend to 
have ALT levels higher than those of AST, this finding is more marked especially when compared 
with the values found in patients with alcoholic fatty liver disease. A retrospective analysis 
performed on a patient with NAFLD found mean ALT values of 83 IU/mL, and AST of 63 IU/mL 
254. Some authors have also postulated how a reduction in the levels of alanine amino-transferases 
can predict a progressive evolution of the pathology in fibrotic terms. This could also by coherent 
with our data. Assessment of serum ALT levels is frequently used to screen for unrecognized liver 
disease. In the context of NASH, however, the true value of this measurement is discussed. Mofrad 
et al. described patients with ALT included within the normal range and who could present any of 
the histological manifestations that make up the broad spectrum of NAFLD. An increase in the 
indices of cytonecrosis has not been shown to be associated with a more severe histological picture, 
in the same way that normal transaminases or reduced ALT levels cannot exclude the concomitant 
presence of hepatic fibrosis 121. Other studies underline how the presence of ALT at the upper limits 
of the norm must in any case be considered as an element of suspicion of an underlying liver 
disease, such as to make the patient who presents them deserving of further diagnostic 
investigations and close clinical and instrumental monitoring 255,256. Kim and co-workers therefore 
proposed, on the basis of the data extrapolated in their work, cut-offs capable of predicting the risk 
of liver disease: ALT values equal to 31 IU/L and 30 IU/L respectively for male and female 256. In 
consideration of the wide variability of the data, measurement methods, available laboratory assays, 
as well as in the light of the absence of a precise and specific definition of high ALT, 
Neuschwander-Tetri et al. note that to date it is not possible to use the value of alanine amino-
transferase as a sufficiently sensitive and specific index to identify those with steatohepatitis among 
patients with NAFLD 257. In our study, patients with NASH had significantly lower AST/ALT 
ratios compared with individuals with NAFL. Many studies in the literature have suggested that an 
AST/ALT ratio above the value of 1 may be suggestive of NAFLD in the absence of significant 
fibrosis. Cichoż-Lach et al. found that patients with progressively higher degrees of fibrosis found 
on histological evaluation presented a progressive increase in the AST/ALT ratio. On the basis of 
these findings, the BAARD score has been elaborated. It incorporates, in addition to the relationship 
between hepatic cytolysis indices, BMI and the presence of diabetes mellitus 258. The same NAFLD 
fibrosis score also uses this first parameter, together with other biohumoral and clinical indices, to 
estimate the degree of hepatocyte fibrosis. Both of these scores have been shown to have a high 
negative predictive value, capable of identifying patients with a low degree of fibrosis and directing 
the others to the biopsy analysis. Our findings also differ from what theoretically expected in the 
light of the available literature data. However, several authors highlight how the dosage of 
transaminases is characterized by a wide variability, even within the normal limits, which does not 
correlate with histological severity, and that there are no threshold limits defined in the different 
populations 259. Finally, it should always be remembered that these enzymes can also be disposed of 
by other tissues and that, in our case, even the low sample size may have influenced the results. 
In our patients, the cholestasis indices were on average within the normal range, thus not showing 
statistically significant differences between the two groups of subjects evaluated. Cholestasis 
indices were also elevated in patients with NAFLD, so much so that some authors suggest that such 
finding in patients with risk factors for the development of NAFLD should be carefully evaluated to 
verify the presence of this pathology 260. 
The hepatic synthesis indices (INR, albumin, Cholinesterase) as well as the bilirubin levels were 
within the normal limits, and this element is easily explained in the light that none of the patients 
evaluated has an advanced degree of liver disease. 
The finding of an increase in ferritin levels, with transferrin saturation values in the normal range, is 
frequently observed in patients with hepatic steatosis. Kodely et al. described histological pictures 
of greater severity in patients with NAFLD and an increase in ferritin up to 1.5 times the normal 
limits (e.g. over 450 ng/mL in men and 300 ng/mL in women). to present with greater degrees of 
steatosis, ballooning, fibrosis and therefore characterized by the presence of NASH. The 
multivariate regression analysis revealed that this ferritin level is independently associated with the 
diagnosis of steatohepatitis but also with hepatic hemosiderosis, with a greater degree of 
inflammation and hepatocyte damage, as well as with a more advanced degree of fibrosis 261. In 
light of these data, its use as a non-invasive test for the detection of hepatocyte damage has been 
proposed. However, in our cohort we did not observe significant differences in ferritin levels 
between the two groups, perhaps due to the lower degree of inflammation and hepatocyte damage.  
Even in terms of C-reactive protein (PCR) we did not observe statistical significant differences 
between patient with NASH and NAFL. This is an opsonin belonging to the pentasserin family, an 
textbook acute phase protein. It is produced by the liver during inflammatory states, following 
various stimuli induced by adipose tissue. Higher plasma CRP levels have been reported in subjects 
with type II DM and metabolic syndrome, and higher CRP concentrations have been described in 
cases of hepatic steatosis and steatohepatitis. It still remains a matter of discussion whether this 
index can be used as a marker capable of distinguishing between these last two conditions, also in 
consideration of the few and controversial data in the literature on the subject, which do not seem to 
demonstrate the existence of a correlation between PCR levels and the histological presence of 
NASH 262,263. 
The haemostatic factors associated with an increased cardiovascular risk are represented by the 
inhibitor of the plasminogen activator (PAI-1), the tissue plasminogen activator (t-PA), the von 
Willebrand factor and fibrinogen. Wild et al. have shown that patients with metabolic syndrome 
have significantly higher values of t-PA, CRP, e-selectin, uricemia and IL-6 than patients without 
this syndrome 264. On a group of healthy non-smoking volunteers, Tarher et al. found that the 
plasma levels of PCR, fibrinogen, von Willebrand factor, and PAI-1 were higher in patients with 
fatty liver than in those who they did not have this condition, regardless of gender, age, BMI, blood 
pressure, IR, and triglyceridemia 265. Concentrations of IL-6 and CRP appear to correlate with 
elevated levels of fibrosis and inflammation in patients with hepatic steatosis, as observed in 
steatohepatitis 266. NAFL and NASH as conditions characterized by chronic inflammation and the 
presence of pro-inflammatory cytokines represents an additional stimulus for the development and 
progression of atherosclerotic disease. Our data revealed the absence of statistically significant 
differences in the levels of PAI-1 and t-PA in the two groups of patients. This finding differs from 
the data available in the literature, perhaps due to the limited sample size. From the work of 
Verrijken and co-workers, it emerges that the levels of PAI-1 are associated with the severity of the 
histological picture of the NAFLD patients. In the multivariate analysis it emerged that the degree 
of steatosis, in particular, appears to be an independent predictor of the levels of PAI-1. However, 
only 12% of the variability could be explained on the basis of the histological findings, and this is 
probably due to the ubiquitous production of expression of this serine protease inhibitor. The 
hypothesis that the increase in PAI-1 levels may derive, at least in part, from hepatocytes, would 
seem to be supported by the detection of higher concentrations of this protein in patients with 
stetohepatitis than in those who were not affected by this condition 267. Moreover, it should be taken 
into consideration first of all that the conditions associated with NAFLD and the metabolic 
syndrome, such as IR, obesity, diabetes mellitus, and sedentary lifestyle favor the induction of PAI-
1 and, secondly, that PAI-1 itself can play a pro-fibrotic role in the liver parenchyma. Further 
studies are needed in order to deepen the clinical picture. 
Patients with NASH demonstrated higher levels of TSH than patients with steatosis alone. This 
finding is consistent if evaluated in the context of the characteristics of these subgroups of patients, 
characterized by a higher body weight, a higher BMI and a more marked IR. The data relating to the 
association between thyroid hormones and NAFLD are still controversial. The former is involved in 
the regulation of body weight, in lipid and energy metabolism, in adipogenesis and in IR. In clinical 
practice, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular 
mortality, and alterations in lipid metabolism 268. A growing literature is also highlighting how there 
is a high prevalence of subclinical hypothyroidism, between 15% and 36%, in patients with 
NAFLD. Several studies have shown that hypothyroidism appears to be an independent risk factor 
for the development of NAFLD, suggesting that hypothyroidism can directly determine the onset of 
NAFLD regardless of the presence of other metabolic risk factors. Considering the results of these 
studies, hypothyroidism can be added to the risk factors of which can induce the development of 
NAFLD 269. The mechanisms by which hypothyroidism would be able to favor the development of 
NAFLD would be mediated by the induction of reactive oxygen species, IR (through an increase in 
FGF-21 and leptin), and alteration of lipid metabolism (increase in triglycerides and cholesterol). It 
is still debated whether there is an association between hypothyroidism and the degree of severity of 
hepatocyte damage, i.e. the presence of steatohepatitis. Chung et al. evaluated a large number of 
healthy patients and found that an increased prevalence of NAFLD and increased serum ALT levels 
could be observed in patients with hypothyroidism 270. An increase in alanine aminotransferase 
concentrations, in this study, appears to be a surrogate biomarker of the presence of NAFLD in the 
absence of other causes of liver disease, and can also be an indicator of risk for the development of 
diabetes, cardiovascular disease, and long-term complications of metabolic syndrome. The work in 
question is however limited by the lack of histological data, an element evaluated in the study 
carried out by Pagada et al. The latter found a higher prevalence of hypothyroidism in patients with 
NASH than in those with steatosis alone. This figure was statistically significant even after the 
correction for variables such as age, diabetes, dyslipidemia, and hypertension 271. Contrary to these 
results, other studies, including those by Mazo et al. have not shown the existence of a statistically 
significant association between hypothyroidism, NAFL, and NASH 272–274. Furthermore, the 
hypothesis has been raised that the alterations in the levels of thyroid hormones can be attributed to 
the so-called euthyroid sick syndrome, or to the presence of concomitant systemic pathologies in a 
subject with normal thyroid functioning 269. It seems reasonable, in consideration of the existing 
association between impaired thyroid function, dyslipidemia, IR, and NAFLD, to evaluate the 
thyroid profile in patients with hepatic steatosis and possibly correct any dystyroidism, as this is a 
modifiable risk factor. Further studies will be performed to evaluate the existence of a possible 
association between NASH and hypothyroidism. 
IGF-1 or somatomedin is produced mainly in the hepatocyte as a result of the stimulus induced by 
growth hormone or GH, but other tissues are also able to produce it given the paracrine and 
autocrine activities of this hormone. It is carried into the circulation by various IGF-1 binding 
proteins, which modulate its activity and release at the tissue level, as well as guaranteeing an 
increase in its half-life. Its activity is mediated by the interaction with its specific receptor (IGF-
1R), which in consideration of its autocrine, paracrine, and endocrine effects appears to be 
ubiquitously expressed in the various tissues of the body. Its effects on fetal growth and 
development, normal bone growth, ovarian follicogenesis, testicular integrity and function, 
cardiovascular development, its cardio-protective effects, and its effects on neuronal development 
and muscle growth have been long since defined and proven 275. In patients with visceral obesity, 
the existence of an altered functioning of the GH/IGF-1 axis has been demonstrated, although the 
mechanisms underlying this phenomenon have not been fully elucidated. It has been postulated that 
at the base there may be an imbalance of the hypothalamic axis with consequently reduced secretion 
of GHRH and/or with an excessive tone of somatostatin. Furthermore, the elevated contractions of 
circulating FFAs can inhibit GH secretion in the pituitary. Even leptin seems to be involved in the 
regulation of GH secretion, albeit in a not fully understood way, but probably acting at the level of 
GHRH and somatostatin 276. The circulating levels of IGF-1 are mainly induced by the secretion of 
GH and through a negative feedback mechanism regulate its production at the hypothalamic level. 
Obese patients tend to have normal or increased levels of total IGF-1 and elevated levels of free 
IGF-1. This finding suggests that other factors besides GH alone can influence circulating levels of 
IGF-1. In particular, excessive caloric intake and a state of hyperinsulinemia could contribute to this 
condition. Furthermore, IR, by inducing a decrease in the production of IGF-1 binding proteins 
(IGF-1BP), contributes to an increase in the levels of free circulating IGF-1, which could therefore 
inhibit the release of GH at the hypothalamic level and favor the development of 
hyposomatostatinemia. In mouse models, it has been shown that IGF-1 deficiency is related to IR, 
alterations in lipid metabolism, damage related to oxidative stress, and alteration of the neuro-
hormonal axis 275. Some authors have found that there is an inverse relationship between the 
circulating levels of IGF-1 and the incidence of the metabolic syndrome, with hepatic steatosis, IR, 
dyslipidemia, and visceral obesity and cardiovascular risk 276–280. All these results suggest a possible 
role of IGF-1 not only in the development of the metabolic syndrome, but also in the 
etiopathognesis of NAFLD itself. This could be attributed to the permissive role towards the 
induction of IR, oxidative stress, and altered lipid metabolism. Being a condition found in both 
NAFLD and metabolic syndrome, it can also be considered that this deficiency represents a 
common passage in the pathways that determine the development of these pathologies. In vivo 
studies have shown how a deficiency in IGF-1 levels is associated with alterations in the cellular 
architecture of the hepatic parenchyma, suggesting how this deficiency may be implicated from the 
earliest stages of hepatocyte damage. A partial deficiency of this hormone could also lead to an 
altered expression at the level of the hepatocytes of the genes encoding the IGF-1 receptor (IGF-1R) 
and the proteins involved in the acute phase and in inflammation, thus favoring the hepatic 
oxidative damage 275. Chishima et al. have shown that elevated GH levels and reduced 
concentrations of circulating IGF-1 can contribute to the progression of metabolic-based liver 
disease 281. In their study, they observed that patients with cirrhosis had low levels of IGF-1, and 
higher levels of GH, compared to those who had lower degrees of fibrosis. Moreover, patients with 
higher degrees of steatosis had reduced GH levels and increased IGF-1 levels. Zhuravlyova et al. 
identified 143.9 ± 4.92 ng/ml as a cut-off value below which there would be an increase in the risk 
of liver disease evolution, suggesting that a reduction in serum IGF-1 concentrations is associated 
with an increase in liver cytolysis , triglycerides, and resistin values 282. The patients involved in our 
study presented on average reduced IGF-1 values, unlike what might be expected in the light of the 
above considerations. Subjects with NASH dosed higher levels of IGF-1 than patients with steatosis 
alone. This finding could be attributable to the small sample considered, which is characterized by 
the absence of high degrees of fibrosis on histological investigation (condition in which the levels 
of IGF-1 should be markedly lower), or on the basis of the characteristics of the subjects included in 
this subpopulation: patients on average younger (it is known that IGF-1 levels decrease with 
increasing age), suffering from higher degrees of obesity (in obesity conditions increased or normal 
levels are observed of IGF-1 and a greater quantity of free circulating IGF-1 276) and a state of more 
marked hyperinsulinemia. The finding of higher mean values in patients with NASH compared to 
those detected in subjects with steatosis, may also lead us to reflect on the greater risk incurred by 
this population of developing a hetoroplastic pathology. In fact, in patients with hepatocarcinoma 
(HCC), the existence of the alteration of the GH/IGF-1 axis and the expression of IGF-1R has been 
demonstrated. SerpnB3 itself would induce an increase in the expression of IGF-1R, through the 
inhibition of miR-122 283, thus promoting oncogenesis. Alterations typically found in HCC and 
hepatoma cell lines include increased expression of IGF-2 and IGF-1 (IGF-IR), crucial elements 
involved in malignant transformation and tumor growth. Alterations in the production and 
degradation of IGF-1 binding proteins and the proteolytic degradation of IGF-BP results in an 
excess of IGF, as well as impaired function of the IGF-2 / mannose 6-phosphate receptor (IGF-2 / 
M6PR), and can further enhance the mitogenic activity of IGFs in favoring the development of 
HCC 284–287. This mechanism could help to favor the development of primary neoplastic pathology 
on non-cirrhotic liver in this subset of patients. The growing interest in this path has led to the 
development of pharmacological research lines for the treatment of HCC based on the inhibition of 
IGF-1R itself 288. 
The limitations of our research are represented above all by the low number of the analyzed sample, 
which was certainly influenced by the strict inclusion criteria. 
Furthermore, patients enrolled with a diagnosis of steatohepatitis are characterized by presenting 
low degrees of firbosis or inflammation on histological examination in images compatible with 
early stages of NASH. Therefore, in the analyzed cohort the broad spectrum of histological pictures 
that characterize a dynamic pathology such as NAFLD (in which the factors contributing to the 
progression of the disease have not yet been fully understood and described) was not fully 
represented. The identification of one or more control groups could be useful to better understand, 
contextualize, and compare the data obtained. 
The use of hepatic needle biopsy as a tool to define the degree and stage of the disease, although 
considered the gold standard by the guidelines for the diagnosis of NASH or NAFL, is limited by 
the fact that this investigation is subject to sampling errors, the biopsy frustule is not representative 
of the entire hepatic parenchyma since the pathologies are heterogeneously distributed throughout, 
and the histological diagnosis is strongly operator-dependent. The elements collected so far allow us 
to describe the baseline characteristics of the population evaluated. To define whether the SCCA-
IgM is able to predict the risk of any progression of liver disease, it will be necessary to continue 
monitoring the enrolled patients in the long term. 
Furthermore, it should be emphasized that there are no studies in the literature that specifically 
evaluate the levels of this immune complex in the histologically characterized population of 
subjects affected by NAFLD. Therefore, there are no ad hoc cut-offs validated for this context. 
In consideration of the fact that NAFLD is a very widespread and often misunderstood, the search 
for soluble markers that can be used in order to make a diagnosis or to stratify the patient's risk of 
presenting a more aggressive and/or advanced disease, deserving of greater diagnostic 
investigations or a more stringent clinical or instrumental monitoring, is the object of fervent 
interest.  
From this perspective, it could therefore be interesting to evaluate in further and prospective studies 
whether SCCA-IgM, alone or in association with other biohumoral and/or clinical indices, for 
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Consistently epidemiologic data has shown, in the last years, a progressive increase in the incidence 
and prevalence of NAFLD/MAFLD due to radical changes in lifestyle, eating habits, and the 
discovery and dissemination of therapy for the treatment of viral hepatitis. This has led to NAFLD 
becoming a major cause of chronic liver disease. It should be noted that it is a subtle pathology that 
is often diagnosed accidentally, given the absence of specific signs or symptoms, except in 
advanced stages in which the typical stigmata of cirrogenic evolution or the presence of HCC are 
appreciable. The gold standard for diagnosis, which at the same time also provides prognostic 
information, giving indications relating to the degree of fibrosis, remains the liver biopsy, an 
investigation that is not free from risks and limitations, certainly not practicable in an extensive 
manner to all patients. Certainly, the greatest unmet need is therefore linked to the lack, in this 
context, of non-invasive markers with diagnostic and prognostic value.  
Due to its wide diffusion, the lack of non-invasive and widespread diagnostic tools, the inadequacy 
of oncological surveillance strategies, even those economically viable, and the absence of ad hoc 
therapies, often only a small percentage of patients with already overt liver disease are adequately 
monitored in order to intercept the possible onset of HCC. It follows that a large percentage of 
subjects at risk escape surveillance programs with the risk of a late diagnosis and in already 
advanced stages of cancer. 
In recent years, increasingly widespread and extensive studies deriving from candidate genes, 
genome-wide association studies and exome-level association studies have made it possible to 
identify SNPs associated with genetic susceptibility and risk of evolution of NAFLD. In particular, 
on the basis of the different designs of the studies developed, the populations and ethnic groups 
considered and the methodology applied, it is estimated that genetic susceptibility plays a role 
ranging from 20 to 70% 289–291.  
Having identified the individual genetic variants and genes involved in predisposition to disease 
onset, many authors have sought to investigate their combined effect on NAFLD susceptibility. 
Approximately from 2009, a lot of research groups have developed studies to examine how genetic 
variants either on their own or combined with each other or other clinical variables can predict the 
presence of liver steatosis, steatohepatitis, and cirrhosis 68,291,292.  
More recently, the genetic impact on NAFLD-HCC development has been intensely researched. In 
2017, Donati et al. developed a genetic and clinical score that combine rs738409 PNPLA3 variant, 
rs58542926 TM6SF2 variant and rs641738 MBOAT7, age, sex, presence of obesity, type 2 diabetes, 
and severe fibrosis in a group of Italian NAFLD-HCC patients. The score as created identifies 
patients with HCC with an AUROC of 0.96 ± 0.04 (96% sensitivity, 89% specificity) 293.  Pelusi 
and coworkers aimed to stratify and discriminate NAFLD-HCC risk by investigating a wide 
inherited pathogenic variant in candidate genes and elaborating a genetic risk score, in a cohort of 
metabolic related HCC, NAFLD with advanced fibroses, and a control group of European, non-
Finnish forefathers. The best threshold resulted 0.22 with an AUROC of 0.74 (61% sensitivity, 76% 
specificity). The genetic risk score result has shown to be better at discriminating the risk of 
developing liver tumor than the single risk variants, even the most common ones (i.e. PNPLA3) or 
the combination of some of them (i.e. PNPLA3 I148M and TM6SF2 E167K). Furthermore, the 
score proved to be associated with the risk of HCC regardless of the classical risk factors. Finally, 
the combination of this score and clinical data allows to optimize the diagnostic yield 294.  Recently, 
Gellert-Kristensen et al. published a study in which they examined whether a genetic risk score 
(GRS) based on a 0 to 6 evaluation of risk-increasing alleles for the three principal genetic variants 
involved in fatty liver disease determination (PNPLA3 I148M, TM6SF2 E167K, HSD17B13 
rs72613567) is able to predict the risk of cirrhosis and hepatocellular carcinoma (HCC) 
development. The data were collect relying on two studies of the Danish General population and 
from the UK Biobank. Data about the diagnosis of cirrhosis or HCC were based on International 
Classification of Diseases (ICD) inferred by the patients and causes of death registers. The genetic 
risk score results showed an up to 12-fold higher risk of cirrhosis and an up to 29-fold higher risk of 
HCC. Furthermore, a high GRS causes a 19-fold increased risk of progression from cirrhosis to 
HCC 295.  
In this landscape and bearing in mind that hepatic fat content is at least 50% genetically determined 
57,68,296–298, we took part in a multicenter cross-sectional cohort study, with the main purpose of 
investigating whether a weighted PRS, based on principal risk alleles affecting genetic 
predisposition to liver fat accumulation and consequent NAFLD development, can predict the risk 
of HCC development in at-risk subject and in the general population.  
We observed that the PRSs values vary according to the severity of liver disease, which was 
particularly well represented for PSR-HCF, reaching statistically significant higher levels in patients 
with HCC. On the other hand, PRS-5 results are higher in patient with severe fibrosis compared 
with those affected from liver tumor. This difference may in part be attributed to the effect of 
HSD17B13, since it has been shown to have a protective effect against the risk of liver disease 
progression 299,300,  specifically by protecting against the development and recurrence of HCC, not 
only direct but also through mitigation of the effect of other genetic variants 299–302 . 
Thought Mendelian Randomization we demonstrated that genetic risk variants confer a risk of HCC 
development that is proportional to the increase of NAFLD risk. Furthermore, a direct connection 
was noticed between the risk of NAFLD and severe fibrosis, and between the latter and HCC. We 
should note that the only exception to the direct relationship between the risk of NAFLD and that of 
HCC was related to the GCKR variant (i.e. the genetic variant with the major known pleiotropic 
effect) which decreases type II diabetes risk, and may thus result in a decreased causal link between 
liver fat and HCC 56 .  
Our results are consistent with the presence of a causal association between hepatic fat content and 
NAFLD-HCC, independent of major clinical risk factors (i.e. sex, age, presence of type II diabetes, 
or obesity), partly due to severe fibroses, even when accounting for pleiotropic effects of the genetic 
instrument. We have estimated that fibrosis has a weight of 65% on the onset of HCC, the 
remaining percentage could be attributable to the HFC share, that’s genetically determinate. 
However, it is not known, and unfortunately our analysis is not able to discriminate, how much the 
risk of HCC is affected by qualitative or quantitative alterations of the hepatic fat content.  
However, these data are consistent with the fact that, as mentioned above, hepatic fat content is 
partially genetically determined and has been shown to influence the development of HCC. This 
consideration can account for cases in which primary liver cancer develops in individuals without 
cirrhosis or high degree of fibrosis 180–182,185,303–306. 
Consistent with previous studies on genetic risk scores, we demonstrated that the PRSs can more 
accurately foretell the risk of developing HCC than single variants. The grade of accuracy is 
moderate, even with an AUROC equal to 0.65 in NAFLD cohort. 
This could represent the exceeding of the current guidelines 7 that considers the evaluation of a 
single genetic variant and, given its stability over a person’s lifespan independently of 
environmental triggers, could be applied to a selected portion of patients and thus could improve 
risk stratification (in term of cirrhosis and HCC development) and help tailor the follow-up. 
We thereafter identified the thresholds for each PRSs (i.e. ≥0.532 and 0.495 for PRS-HFC and PRS-
5, respectively) with the best predictive value with the aim to pick out NAFLD-HCC in the NAFLD 
cohort. We observed that subjects with a PRS over this cut-off present a > 3-fold higher adjusted 
OR of HCC.  
Interestingly, PRS-HCF has been shown to be able to identify patients at risk of developing HCC 
even considering subjects over the age of 40 and diabetics, regardless of the degree of hepatic 
fibrosis, and PRS-5 demonstrated good performance in non-obesity individuals. 
We could therefore hope to use these scores, after their validation in larger populations, alone or in 
combination with other clinical data or biomarkers, to intercept patients with metabolic liver 
diseases at risk of evolution/progression in selected subgroups, including those with no evidence of 
cirrhosis or severe fibroses.  
The deviation and lack of significance obtained from the data analysis applied to the subgroup of 
patients enrolled in our Center, compared to the complete cohort, is attributable to the reduced 
sample size.  
Finally, we did not observe a significant relationship between SCCA-IgM and PRSs. This can be 
explained by considering the pathophysiological basis of the two mechanisms studied: the gene 
variants are mainly associated with the hepatic fat content, while SCCA-IgM induced by oxidative 
stress and chronic inflammatory processes has been shown to be associated with hetrosplastic 
evolution and development of fibrosis. Another limitation could be represented by the low number 
of patients in whom we evaluated both non-invasive biomarkers. 
Similarly, the statistically significant association observed between SCCA-IgM and the P446L 
polymorphism of the GCKR gene is likely to be random. In literature and from a pathophysiological 
point of view at the moment there are no data correlating the constitutive activation of the glucose 
up-take at the hepatocyte level, with consequent increase in the production of malonyl-COA and 
induction of lipogenesis (elements observed in carriers of the variant of the rs1260326 mutation of 
the GCKR gene) 72 with the induction of SCCA-IgM, secondary to chronic inflammation and 
oxidative stress 129,138,165,307. 
Our study is at the moment unique in literature. Compared to previous similar studies 205,293–295, we 
used a robust instrument estimating inherent predisposition of HFC to develop a polygenic risk 
score, based on the principal genetic variants weighted by their effect size on HFC. A consistent 
inference emerged on the causal relationship between the role played by the hepatic fat content and 
the development of HCC, only partially mediated by the presence of fibrosis, a major independent 
risk factor for the development of primary liver cancer. Moreover, we evaluated the score on a well 
characterized population of at risk-subjects and in the general one, even stratifying the analysis 
according to fibroses severity, finding a threshold able to predict the risk of HCC devilment even in 
subjects without significant fibrosis, obesity, or relatively young age. 
However, the study is not without limitations: first of all, the cross-sectional design. In fact, this 
type of study provides a snapshot of the analyzed cohort, in which exposure and outcome are 
assessed simultaneously at the time of enrollment. It should also be considered that there are no data 
relating to the average duration of the disease in the various groups of patients analyzed.  
A further limitation, indeed, is represented by the fact that the subjects enrolled in the control group 
and those with NAFLD and low degree of firbosis are characterized by a significantly lower 
average age than patients with more advanced degrees of firbosis and HCC (as we have seen 
according to literature data, the age and duration of the disease influence the risk of evolution of 
NAFLD). 
Furthermore, the results apply only at subjects with a European (non-Finnish) origins, the only 
ancestry studied. It will be interesting to extend the study to other ethical groups or to specific 
genetic isolates present in Italy or Europe.  
Finally, information on eating habits or lifestyle was not collected in an extensive and uniform 
manner. More generally, there are no data on environmental risk factors that may interact with the 
patient's genetic substrate variants and contribute to to, trigger, or favor the development and 
progression of NAFLD. 
Prospective studies will therefore be necessary to assess the magnitude of the increase in HCC risk 
conferred by PRS more accurately. In the future, the integration in the PRS of other SNP (e.g. HFE 
and SERPINA1 mutations observed for Europeans308, or ADIPOQ, COL13A1, and SAMM50 genes 
detected in Mexican populations309) involved in the risk of developing HCC or with protective 






NAFLD has become the main chronic liver disease in the world and includes a broad histological 
spectrum that extends from simple steatosis to steatohepatitis, up to cirrhosis and HCC. 
In the population, the percentage of patients with steatohepatitis is much lower than that with 
steatosis alone; the prevalence of both conditions is difficult to define, and the data in our 
possession probably underestimate its actual scope, if we consider how widespread the metabolic 
syndrome and the pathologies that constitute it are in the population. 
A growing literature shows how, in patients with NAFLD, cases of hepatocarcinoma are not 
infrequently observed in the absence of overt liver cirrhosis. Such heteroplasias are often more 
aggressive, diagnosed late and therefore burdened with high mortality rates and low therapeutic 
responses. 
Liver biopsy is the gold standard for making a diagnosis, and it is also the only tool that currently 
allows to distinguish between NASH and NAFL. 
Given the vast prevalence of the disease and the disadvantages associated with carrying out this 
diagnostic procedure, great interest has been placed on the search for non-invasive markers for the 
diagnosis of these two conditions. 
Over the years, various soluble markers, radiological tools and scores have been proposed resulting 
from the association of clinical and biohumoral data that could at least serve as a tool for selecting 
patients to be subjected to level II or more invasive investigations and assessments. 
The objective of our study is to evaluate non-invasive biomarkers to stratify the risk of disease 
evolution of NAFLD subject. First of all, in the light of the data described by Martini et al. we 
studied the role of SCCA-IgM, in particular we try to verify whether the serum levels of this 
immunocomplex were associated with the progression of histological damage, in particular the 
presence of NASH. We observed that patient with histological diagnosis of NASH present 
significantly higher concentrations of the immunocomplex. The levels of SCCA-IgM, on linear 
correlation analysis, are associated with the BMI, the age of the patients and the levels of 
homocysteinemia. 
The continuation of the study, with the clinical and laboratory follow-up of the selected patients will 
allow us to evaluate whether the SCCA-IgM immunocomplex may be a marker of evolutionary 
metabolic liver disease towards liver cirrhosis and primary liver cancer. Moreover, higher levels of 
SCCA-IgM were detecting in whom present higher degree of fibrosis at the histology exam.  
According to the linear correlation analysis, SCCA-IgM levels correlated with BMI, age, 
homocystein levels, and with the histological grading of fibrosis. We have to point out that there are 
no studies in the available literature evaluating the role of this immuno-complex in a cohort of 
NAFLD histologically characterized. No ad-hoc cut-offs are available for this population. 
The clinical and laboratory follow-up of our patients will allow us to further evaluate whether 
SCCA-IgM (alone or included in a novel clinical and biochemical score), might represent a marker 
of progression to cirrhosis and primary liver tumour. Recruitment of new cases across different 
stages of NAFLD spectrum will be crucial to further confirm the present data. 
The second non-invasive biomarker that we chose to examine are the principal genetic variables 
involved in lipid metabolism pathways and in hepatic stellate cells function, combined in a had hoc 
score defined by adding the predisposing alleles weighted by their effects size.  
The results of the study are consistent with a causal role of hepatic fat accumulation in liver 
carcinogenesis. PRSs may be useful to non-invasively predict the risk of HCC in subjects with 
NAFLD, independently of the presence of severe liver fibrosis, even in non-obese and young 
individuals. We demonstrated that a positive PRS allow clinicians to identify a subset of individuals 
with dysmetabolism at high genetic risk of HCC development. Therefore, PRSs may be useful to 
stratify NAFLD-HCC risk and guide and improve cancer surveillance strategies 
Large studies integrating genetic and other biomarkers are necessary to further improve the risk 
stratification and promote the clinical and wide application of these results. 





Figure 1. Three different histological pictures characterized by a progressive increase degree in 




Figure 2. NASH Clinical Research Network Histologic Scoring System definition and scores in 








Figure 4. SerpinB3, cistein-proteinasi inibhitor, represents a turning point between inflammation 





Figure 5. SerpinB3, cistein-proteasi inhibitor, involved in cellular proliferation process and in the 





Figure 6. SCCA-IgM levels in NASH and NAFL. SCCA-IgM levels were significantly higher in 







Figure 7. Comparison of SAF score according to I and IV quartiles of SCCA-IgM concentrations ( 
p<0.05). I, II, III, IV quartile medium concentrations of SCCA-IgM: 1.98 ua/mL, 4.11 ua/mL, 7.95 
ua/mL, 35.31 ua/ml. In white are represents I quartile, in light blue IV quartile.  
P = 0.007 
 











Figure 9. Mendenlian Rondomization.  Genetic risk variants confer a risk of HCC development that 
is proportional to the increase in the risk of NAFLD (figure B). A direct relationship is observed 
between the risk of NAFLD and severe fibrosis, and between severe fibrosis and HCC. 















































































Figure 11. Performance test: comparison of the diagnostic accuracy of the PRS-HFC and the PRS-5 
for NAFLD-HCC in the NAFLD cohort. The AUROC of the two PRSs to predict NAFLD-HCC 
and the optimal diagnostic thresholds are shown (the best cut-off for PRS-HFC result 0.532, with an 











Figure 12. Sensitive analysis. Ability of PRSs to predict the risk of developing NAFLD-HCC in 
different subgroups at risk
Figure 4
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Lipodystrophy HELLP syndrome 
Starvation 
Inborn errors of metabolism (e.g., LCAT 
deficiency, cholesterol ester storage 
disease, Wolman disease) 
Parenteral nutrition  
Abetalipoproteinemia  
Medications (e.g., amiodarone, methotrexate, 
tamoxifen, corticosteroids)  
Non-tropical sprue  
Tesaurismosis (galactosemia, glycogenosis, 
tyrosinemia, fructose intolerance)  
 



















Some ballooning-form cells 









>4 foci/20 x 
 
Table 2. NAS score, evaluation of the degree of activity proposed by the Nonalcoholic 






Perisinusoidal or periportal 
a. Mild, zone 3, perisinusoidal 
b. Moderate, zone 3, perisinusoidal 
c. Portal/periportal 
2 Perisinusoidal and portal/periportal 
3 Bridging fibrosis 
4 Cirrhosis 
 
Table 3. NAS score, evaluation of the stage of fibrosis proposed by the Nonalcoholic Steatohepatitis 




Histological figure Score Criterion 
















Some ballooning-form cells 


















Mild, zone 3 perisinusoidal/pericellular 
Moderate, zone 3 perisinusoidal/pericellular  
Portal/periportal 
Perisisusoidal/periportal e portal/periportal 
Bridging fibrosis  
Cirrhosis 
 





 NAFL (n=39) NASH (n=45) p 
Age (years) 57.4±1.6 50.7±2.8 0.03 
Weight (kg) 85.9±2.5 97.2±4.7 0.02 
BMI (kg/m2) 29.1±0.6 34.9±1.7 0.001 
Weist (cm) 102.2±2.1 101.8±3.2 Ns 
Subcutaneous fat. 
(mm) 23±1 24±3 Ns 
Visceral fat (mm) 69±3 64±5 Ns 
Glycemia (mg/dL) 103.9±4.0 100±3.7 Ns 
Insulin (mUI/L) 23.9±6.2 49.5±29.7 Ns 
HOMA-I 4.1±0.4 5.2±1.1 Ns 
HbA1c (%) 6.2±0.1 6.5±0.2 Ns 
Total Cholesterol 
(mg/dL) 200±5 222±8 0.02 
HDL Cholesterol 
(mg/dL) 56±3 55±2 Ns 
LDL Cholesterol 
(mg/dL) 116±5 138±7 0.01 
Tryglicerids (mg/dL) 143±10 158±18 Ns 
AST (U/L) 30±2 28±2 Ns 
ALT (U/L) 39±2 31±4 0.05 
AST/ALT 1.4±0.1 1.1±0.1 0.01 
γ-GT (UI/L) 65±9 93±31 Ns 
Total Bilirubin 
(mg/dL) 0.7±0.1 0.7±0.1 Ns 
Pseudocholinesterase 
(UI/L) 8818±236 9322±404 Ns 
Homocysteine 
(µmol/L) 13.4±0.8 12.8±0.6 Ns 
PCR (mg/L) 9.9±0.3 3.7±1.2 Ns 
PAI 19.8±4.8 14±2.2 Ns 
tPA 10.3±1.0 7.5±0.8 Ns 
Lp(a) 25±6 21±6 Ns 
Ferritin (ng/ml) 213±32 179±41 Ns 
TSH  (mU/L) 1.4±0.1 2.2±0.2 0.001 
IGF-1 (ng/ml) 97±7 122±15 Ns 
Cortisol 361±22 323±44 Ns 
SCCA-IgM (ua/mL) 9.2±1.8 31.7±7.2 0.007 
 
Table 5. Anthropometric, biohumoral, and ultrasound baseline data characteristics in patients with 






SCCA-IgM vs r n p 
Age (years) 0.269 64 <0.05 
Waist (cm) 0.08 54 Ns 
BMI (kg/m2) 0.30 64 0.01 
Visceral fat (mm) 0.16 54 Ns 
Subcutaneous fat (mm) 0.06 54 Ns 
Homocysteine (µmol/L) 0.33 54 0.02 
AST (U/L) 0.12 54 Ns 
ALT (U/L) 0.06 54 Ns 
AST/ALT 0.15 54 Ns 
NAS score* 0.18 54 Ns 
Steatosis grade* 0.17 54 Ns 
SAF-S* 0.17 54 Ns  
SAF-A* -0.14 54 Ns 
SAF-F* 0.29 54 <0.05  
 
Table 6. Correlation between SCCA-IgM and demographic, biochemical, and histological variables 




















Age 44 ± 6 42 ± 16 58 ± 14 69 ± 9 <.0001 
Sex, M 455 (52.6) 677 (57.6) 171 (57.6) 178 (78.8) <.0001 
T2D, yes 8 (0.9) 238 (20.2) 169 (56.9) 145 (64.2) <.0001 
BMI, 
Kg/m2 
25.3 ± 5.0 32.7 ± 8.6 30.7 ± 5.1 30.2 ± 5.6 <.0001 


























Method Estimate SE 95% c.i. p value 
Weighted median 1.018 0.188 0.650 - 1.387 <0.001 
Robust IVW 0.969 0.226 0.526 - 1.412 <0.001 
Robust MR-Egger 0.998 0.190 0.627 - 1.370 <0.001 
 
Table 8. Comparison of causality estimates of HFC on HCC by different Mendelian randomization 
approaches taking into consideration possible horizontal pleiotropic effect of the variants under 




 PRS-HFC PRS-5  
AUROC 0.64 0.65 
Diagnostic threshold 0.532 0.495 
Prevalence (%)  569 (22.2) 580 (22.9) 
OR (95% c.i.) 3.0 (2.2-3.9) 2.9 (2.1-3.8) 
p value* 3.7*10-14 8.1*10-13 
Sensitivity (95% c.i.) 0.43 (0.37-0.49) 0.43 (0.37-0.50) 
Specificity (95% c.i.) 0.80 (0.78-0.81) 0.79 (0.77-0.81) 
PPV (95% c.i.) 0.17 (0.14-0.20) 0.16 (0.13-0.19) 
NPV (95% c.i.) 0.93 (0.92-0.94) 0.94 (0.93-0.95) 
LR+ (95% c.i.) 2.13 (1.79-2.52) 2.06 (1.74-2.54) 
LR- (95% c.i.) 0.71 (0.64-0.80) 0.72 (0.64-0.81) 
 





 p value* OR 95% c.i. 
PRS-HFC ≥ 0.532 6.5*10-4 1.9 1.3-2.8 
PNPLA3 3.4*10-2 1.5 1.1-2.3 
TM6SF2 8.4*10-2 1.5 0.9-2.4 
MBOAT7 8.6*10-1 1.0 0.7-1.5 
GCKR 5.8*10-1 0.8 0.6-1.4 
HSD17B13 3.8*10-2 0.5 0.2-1.0 
PRS-5 ≥ 0.495 4.3*10-4 2.0 1.3-2.9 
 
Table 10. Both PRS resulted superior to single variants for predicting NAFLD-HCC (*Adjusted for 









(n=19) HCC (n=30) p-value 
Age, 
years 45 ± 6 57 ± 9 59 ± 9 65 ± 9 5,00E-94 
Sex, M 432 (55.9%) 22 (66.6%) 8 (42.1%) 21 (70.0%) 1,40E-01 
BMI, 
Kg/m2 24.1 ± 1.9 28.2 ± 4.0 31.0 ± 4.1 29.3 ± 6.7 2,50E-64 



















Table 11. Baseline characteristics of 82 patients enlisted from Udine in the NAFLD study cohort.  
 
Table 12  
 




  Model 
2 
  
  p-value OR 95% c.i. p-value OR 
95% 
c.i. p-value OR 
95% 
c.i. 
           
PRS-






40.9 - - - 
 Fibrosis 






19.2 - - - 









           




63.2 - - - 
 Fibrosis 




01 0.5 0.1-3.6 - - - 










Table 12. PRS-HFC and PRS-5 as predictors of liver disease in Udine subgroup (Model 1: adjusted 





p-value° OR 95% c.i. p-value* OR 95% c.i. 
PRS-HFC ≥0.532 2,20E-05 5.1 2.4-10.7 3,70E-01 1.7 0.5-5.4 
PRS-5 ≥0.495 4,50E-04 4.1 1.9-8.9 5,30E-01 1.5 0.4-4.7 
PNPLA3 I148M, carrier 1,80E-03 3..9 1.7-9.2 4,30E-01 1.6 0.5-5.0 
TM6SF2 E167K, carrier 3,00E-01 1.6 0.6-4.1 2,20E-01 2.2 0.6-8.3 
MBOAT7 rs641738 C>T, carrier 7,20E-01 1.2 0.5-2.6 1,40E-01 0.4 0.1-1.3 
GCKR P446L, carrier 4,30E-01 1.4 0.6-3.6 7,80E-01 0.8 0.2-2.9 
HSD17B13 rs72613567:TA, 
carrier 
3,70E-01 0.7 0.3-1.5 5,60E-01 0.7 0.2-2.3 
 
Table 13. Comparison of PRSs vs. single variants for the prediction of HCC (° At logistic 





PRS-HFC  PRS-5  PRS-HFC° PRS-5° PRS-HFC* PRS-5* 
AUROC 0.72 0.70 
    




















    


























    




    




    




    




    
 
Table 14. Diagnostic accuracy of PRS-HFC and PRS-5 for HCC in subgroup of Udine patients (° 







Estimate SE 95% c.i. p-value 
PNPLA3 I148M, carrier -0.02 0.07 -0.16 - 
0.11 
7,22e-1 
TM6SF2 E167K, carrier 0.01 0.08 -0.16 - 
0.16 
9,9e-1 
MBOAT7 rs641738 C>T, carrier -0.05 0.09 -0,23 - 
0.13 
6,03e-1 
GCKR P446L, carrier -0.16 0.08 -0.32 - -
0.01 
4,07e-2 
HSD17B13 rs72613567:TA, carrier 0.05 0.07 -0.08 - 
0.19 
4,29e-1 
PRS-HFC ≥0.532 -0.06 2.14 -0.35 - 
4.21 
9,75e-1 




Table 15. Association between genetic variants/PRS and SCCA-IgM levels.  
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